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Abstract 
Recently, two novel 4-substituted phenylthiazoles, D1 and D2, have been synthesised based 
upon the marine bacterial secondary metabolite anithiactin A/thiasporine C, and shown to be 
cytotoxic towards cancer cells below 100 µM, with suggestions of inhibition of tubulin 
polymerisation. D1 and D2 were then further screened for cytotoxicity in three cancer cell lines 
(MDA-MB-231, MCF-7, HT-29) and one non-transformed mesenchymal stem-cell line 
(RCB2157), using the MTT assay. Their effects on the cell cycle and cell death mechanisms 
were analysed using flow cytometry and fluorescent microscopy and spectroscopy. 
Unfortunately, no significant changes in cell death mechanisms were observed and previous 
cytotoxicity results were unable to be replicated. This was attributed to the degradation of the 
compounds in DMSO solution, likely to cause a loss in biological activity. 
Antihelminthic benzimidazole drugs mebendazole and albendazole are commonly used to treat 
a variety of worm infestations in humans. Their mechanism of action against helminths is well-
established and involves the inhibition of microtubule formation. Mebendazole has recently 
shown promising results in pre-clinical in vitro and in vivo cancer studies and is currently in 
Phase I trials for treatment of glioma. However, the way in which it causes cell death in cancer 
cells has not been fully explored. 
Here, the in vitro analysis of the anticancer mechanism of action of mebendazole and a 
structural analogue albendazole was undertaken.  The two drugs were screened for cytotoxicity 
in three cancer cell lines (MDA-MB-231, MCF-7, HT-29) and one non-transformed 
mesenchymal stem-cell line (RCB2157), using the MTT assay. Their effects on the cell cycle 
and cell death mechanisms were analysed using flow cytometry and fluorescent microscopy 
and spectroscopy. 
Mebendazole and albendazole were found to selectively kill cancer cells, being most potent in 
the colorectal cancer cell line HT-29, with IC50 values of 1.3 ± 0.1 µM and 1.4 ± 0.1 µM, 
respectively. Both mebendazole and albendazole induced caspase-3 activation. 
Phosphatidylserine exposure, mitochondrial and lysosomal membrane permeability and 
reactive oxygen species production were all significantly increased compared to control and 
peaked at 24 hours, with DNA fragmentation increasing in a time-dependent manner peaking 
at 48 hours. Using Hoechst 33342 staining, nuclear features of apoptosis such as chromatin 
condensation were found following treatment with both drugs. Cell cycle arrest in the G2/M 
phase was found, and tubulin structures were significantly altered. Mebendazole and 
albendazole appear to cause cancer cell death via a mechanism of classical apoptosis and cell 
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Chapter 1:  Introduction 
 
 1.1 Cancer 
Cancer is a range of diseases defined by the abnormal, uncontrolled growth of cells in a variety of 
tissue types. It is caused by mutations in various genes responsible for cell proliferation, 
differentiation, survival, DNA repair and cell death or apoptotic control. Cancer is a leading cause of 
morbidity and mortality in New Zealand, accounting for nearly one third of all deaths. Among the 
many types of cancers, lung, colorectal, prostate and breast cancers are the biggest killers in New 
Zealand (Ministry of Health. 2016). Each year approximately 1200 people in New Zealand die of 
colorectal cancer, a mortality rate similar to breast and prostate cancers combined (BPAC, 2012). 
Chemotherapy is one of the primary treatment methods used to combat these cancers. Traditional 
chemotherapy agents need to be used at high therapeutic doses, which often result in detrimental side 
effects for patients, reducing quality of life of the patient and also the effectiveness of the therapy. 
Additional issues with chemotherapy involve the development of resistance to therapeutic drugs, 
through a variety of possible mechanisms such as resistance-associated point mutations, altered 
membrane transport, activated DNA repair systems, and altered enzyme activity (Raguz et al., 2008). 
The growing resistance to the available anticancer drugs thus drives the search for novel anticancer 
compounds, which may potentially be used as new chemotherapeutic agents.   
1.2.  Apoptosis 
The term apoptosis was first used in a now-classic paper by Kerr, Wyllie, and Currie in 1972 to 
describe a morphologically distinct form of cell death, although certain components of the apoptosis 
concept had been explicitly described many years previously (Kerr et al., 1972; Paweletz, 2001; Kerr, 
2002). Apoptosis is commonly referred to cellular suicide and occurs normally during development 
and aging and acts as a homeostatic mechanism to maintain cell populations in tissues, such as in the 
overproduction of cells giving rise to the nervous and immune systems. This initial overproduction is 
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then followed by the death of those cells that fail to establish functional synaptic connections or 
productive antigen specificities, respectively (Nijhawan et al., 2000; Opferman et al., 2003). 
Apoptosis also occurs as a defence mechanism such as in immune reactions when cells are damaged 
by pathogenic or noxious agents, and is a vital component of wound healing in that it is involved in 
the removal of inflammatory cells and the evolution of granulation tissue into scar tissue (Greenhalgh, 
1998; Norbury et al., 2001). Apoptosis is morphologically classified by cell shrinkage, chromatin 
condensation (pyknosis), nuclear fragmentation and membrane blebbing which are indicative of the 
execution phase of apoptosis (Kerr et al., 1972; Elmore, 2007). There are two main apoptotic 
pathways: the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway, both of 
which rely on the cleavage of pro-caspases to execute apoptosis, however an additional caspase-
independent, granzyme/perforin-mediated pathway has been described (Fan et al., 2003; Elmore, 
2007). The caspases involved are divided into ‘initiator’ caspases (caspase-8 and -9) and ‘effector’ 
caspases (caspase-3, -6 and -7) which are responsible for the execution phase of apoptosis (Fesik et 
al., 2001; Delgado et al., 2013). 
1.2.1 Intrinsic Pathway 
In the intrinsic pathway, death signals caused by various stimuli, including heat stress and radiation, 
act directly or indirectly on the mitochondria to cause the release of pro-apoptotic proteins from their 
intermembrane space. This cell death pathway is generally thought to be controlled by Bcl-2 family 
proteins (involved in the regulation of cytochrome c release), inhibitor of apoptosis proteins (IAPs) 
(inhibition of caspases), second mitochondrial-derived activator of caspases (SMAC), and Omi 
(negative regulation of IAPs) (Orrenius et al., 2011). The initial stages of the intrinsic pathway are 
regulated by the Bcl-2 family of proteins, which govern mitochondrial membrane permeability and 
can be either pro-apoptotic or anti-apoptotic (Cory et al., 2002; Kim et al., 2009). To date, a total of 
25 genes have been identified in the Bcl-2 family. Some of the anti-apoptotic proteins include Bcl-2, 
Bcl-x, Bcl-XL, Bcl-XS, Bcl-w, BAG, and some of the pro-apoptotic proteins include Bcl-10, Bax, 
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Bak, Bid, Bad, Bim, Bik, and Blk (Cory et al., 2002; Elmore, 2007). The pro-apoptotic members are 
divided into a further subclass known as the BH3-only proteins (BH3s) of which Bim, Bid, Puma and 
Bik are members. BH3s are responsible for activating Bax and Bak, which then go on to alter the 
mitochondrial outer membrane integrity, the critical step in intrinsic apoptosis which leads to 
cytochrome C release and subsequent caspase activation (Youle et al., 2008). A few possible 
mechanisms for the activation of Bax and Bak by BH3s have been studied, but none have been proven 
definitively (Elmore, 2007). 
Once activated by BH3 proteins, Bax translocates from the cytosol to the mitochondria, where it 
inserts into the outer membrane via its C- terminal and then proceeds to form homo-oligomers (Kim 
et al., 2009).  Bak behaves in the same way once activated, however it does not require translocation 
as it is an integral mitochondrial membrane protein 
(Dewson et al., 2009). The BH3 domain-only protein t-
Bid then facilitates the activation and oligomerisation 
of Bax and Bak to form MAC (Mitochondrial 
Apoptosis-Induced Channel), which can be 
predominantly composed of either Bax or Bak (Figure 
1). The anti-apoptotic protein Bcl-2 suppresses MAC 
formation (Dejean et al., 2006). Once formed, the MAC 
pore aids the release of cytochrome c, SMAC, Omi and 
apoptosis inducing factor (AIF) which all promote apoptosis. SMAC and OMI act by binding and 
inhibiting x-linked inhibitor of apoptosis protein (XIAP) which normally inhibits caspase-9, -3 and -
7 (Verhagen et al., 2000; Suzuki et al., 2001). Cytochrome c goes on and binds to the regulatory 
domain of apoptotic protease activating factor-1 (Apaf-1) (Yuan et al., 2010). This stimulates dATP 
binding to Apaf-1 leading to Apaf-1 activation (Kim et al., 2005b). Once activated, Apaf-1 homo-
oligomerises to form a circular structure known as the apoptosome (Figure 2). The apoptosome 
contains seven activated Apaf-1 molecules associated with one cytochrome c molecule each (Yuan 
Figure 1: Diagram of MAC formation. From 
(Dejean et al., 2006). 
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et al., 2010). The assembled apoptosome recruits and activates procaspase-9, by cleaving the caspase 
recruitment domain (CARD) (Kim et al., 2005a). This in turn activates the proteolytic caspase 
cascade. The now active initiator caspase, caspase-9, cleaves the procaspases giving rise to the 
effector caspases, caspase-3, -7 and -6, and leads to degradation of cellular components for apoptosis, 
resulting in the morphological changes previously described (Logue et al., 2008).  
1.2.2  Extrinsic Pathway 
The extrinsic signalling pathways that initiate 
apoptosis involve transmembrane receptor-mediated 
interactions. These include death receptors that are 
members of the tumour necrosis factor (TNF) receptor 
gene superfamily such as TNF receptor 1 (TNFR1), 
FasR, TRAILR1/2 and Death Receptor 4 (DR4) 
(Locksley et al., 2001). The sequence of events that 
define the extrinsic phase of apoptosis are best 
characterized with the FasL/FasR and TNF-α/TNFR1 
models (Elmore, 2007). TNF-α is a cytokine produced 
mainly by activated macrophages, and is the major 
extrinsic mediator of apoptosis. It binds to TNF 
receptors and results in the binding of the adaptor 
protein TNF receptor-associated death domain (TRADD) with recruitment of Fas-associated death 
domain protein (FADD) and RIP. The binding of Fas ligand to Fas receptor also results in the binding 
of the adaptor protein FADD (Hsu et al., 1995; Wajant, 2002). FADD then associates with 
procaspase-8 via dimerization of the death effector domain. At this point, a death-inducing signalling 
complex (DISC) is formed, resulting in the auto-catalytic activation of procaspase-8 (Kischkel et al., 
1995). Once caspase-8 is activated, the execution phase of apoptosis is triggered and is where the 
intrinsic and extrinsic pathways of apoptosis conjoin (Fig 6). Death receptor-mediated apoptosis can 
Figure 2: Diagram detailing major steps in 
the intrinsic and extrinsic pathways of 
apoptosis. From (Tait et al., 2010). 
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be inhibited by a protein called c-FLIP which will bind to FADD and caspase-8, rendering them 
ineffective (Kataoka et al., 1998; Scaffidi et al., 1999). Another point of potential apoptosis regulation 
involves a protein called Toso, which has been shown to block Fas-induced apoptosis in T cells via 
inhibition of caspase-8 processing (Hitoshi et al., 1998).  
The extrinsic and intrinsic pathways both end at the point of the execution phase, considered the final 
pathway of apoptosis. It is the activation of the execution caspases that begins this phase of apoptosis. 
Execution caspases activate cytoplasmic endonuclease, which degrades nuclear material, and 
proteases that degrade the nuclear and cytoskeletal proteins. Caspase-3, caspase-6, and caspase-7 
function as effector or “executioner” caspases, cleaving various substrates including cytokeratins, 
PARP, the plasma membrane cytoskeletal protein α-fodrin, the nuclear protein NuMA and others, 
that ultimately cause the morphological and biochemical changes seen in apoptotic cells (Slee et al., 
2001; Elmore, 2007). Caspase-3 is considered to be the most important of the executioner caspases 
and is activated by any of the initiator caspases (caspase-8, caspase-9, or caspase-10). Caspase-3 
specifically activates the endonuclease Caspase-Activated-DNase (CAD). In proliferating cells CAD 
is complexed with its inhibitor, ICAD. In apoptotic cells, activated caspase-3 cleaves ICAD to release 
CAD (Sakahira et al., 1998). CAD then degrades chromosomal DNA within the nuclei and causes 
chromatin condensation, by cleaving DNA at internucleosomal linker sites between nucleosomes, 
protein-containing structures that occur in chromatin at approximately 180-bp intervals (Enari et al., 
1998; Sakahira et al., 1998). This apoptotic characteristic can be easily detected following cell 
fixation, where the fragmented DNA multimers leak out of the cells, leaving a population of cells 
with reduced DNA content which can be quantified using DNA-binding dyes such as propidium 
iodide (PI) with flow cytometry (Riccardi et al., 2006; Kajstura et al., 2007). Caspase-3 also further 
induces cytoskeletal reorganization into the apoptotic microtubule network (AMN) and disintegration 




 Necrosis  
Necrosis is commonly thought of as an unregulated form of cell death brought on by such cellular 
insults as infection or toxins. Traditionally necrosis is identified morphologically by the swelling of 
organelles, increased cell volume, disruption of the plasma membrane and loss of intracellular 
contents (Rello et al., 2005). It is the less desirable form of cell death as the release of cellular contents 
into the surrounding extracellular matrix results in an inflammatory response which leads to tissue 
damage (Rock et al., 2008). This is contrasted with the “clean” and organised response seen with 
apoptosis, where cells undergoing apoptotic cell death have externalised phosphatidylserine residues, 
which provide an “eat me” signal to phagocytic macrophages and are then internalised and recycled, 
leaving no immune response (Fadok et al., 1992). 
 Lysosomes in Cell Death 
Lysosomes are small vesicular organelles that serve as cellular recycling centres and are responsible 
for the breakdown of a variety of biomolecules, into nutrients and building blocks for future cellular 
components. The lumen of lysosomes are maintained at a low pH (4.5 – 5) by membrane-bound V-
ATPase proton pumps, which drive protons across the lysosomal membrane into the lumen, providing 
optimal conditions for the various lysosomal hydrolases to carry out their functions (Mindell, 2012). 
Lysosomes contain many different types of hydrolytic enzymes including cathepsins, lipases, 
nucleases, glycosidases, phospholipases, phosphatases and sulfatases (Boya et al., 2008a).  
Lysosomal membrane permeabilisation (LMP) is a potentially lethal event whereby the rupture of the 
lysosome causes the release of these cathepsins and other hydrolases from the lysosomal lumen into 
the cytosol, setting off indiscriminate degradation of cellular components. LMP can be caused by a 
plethora of stimuli, including pharmacological lysosomotropic compounds, reactive oxygen species 
and endogenous cell death effectors such as Bax (Kagedal et al., 2001a; Boya et al., 2003; Yu et al., 
2003; Kagedal et al., 2005; Feldstein et al., 2006; Terman et al., 2006). A quantitative relationship 
between the amount of lysosomal rupture and the mode of cell death has been suggested to explain 
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the widely different morphological outcomes following LMP (Kagedal et al., 2001b). With extensive 
lysosomal leakage caused by high intensity stresses, cytosolic acidification occurs and the cell 
undergoes uncontrolled necrosis. However, partial or selective LMP, caused by low stress intensity, 
triggers limited release of lysosomal contents to the cytoplasm followed by apoptosis or apoptotic-
like death. Accordingly, low concentrations of sphingosine, an acid ceramidase-generated metabolite 
of ceramide with detergent-like properties at low pH, induces partial LMP and caspase-mediated 
apoptosis, whereas higher concentrations result in massive LMP and caspase-independent necrotic 
cell death (Kagedal et al., 2001b). LMP-induced apoptosis is usually activated due to the leakage of 
lysosomal proteases such as cysteine cathepsins B and L and aspartyl cathepsin D, which remain 
active at neutral pH (Boya et al., 2008a; Aits et al., 2013b). These cathepsins then go on to initiate 
MOMP (mitochondrial outer membrane permeabilisation) by cleavage of pro-apoptotic proteins 
(Bid) or inhibiting cleavage of anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL and Mcl-1) (Cirman et 
al., 2004; Droga-Mazovec et al., 2008; Appelqvist et al., 2012). Cytosolic cathepsins can also activate 
apoptotic caspases themselves, by cleaving either them or their inhibitor E3 ubiquitin-protein ligase 
XIAP, which can further enhance either MOMP-dependent or -independent apoptotic death 
(Vancompernolle et al., 1998; Zhao et al., 2003; Conus et al., 2008; Droga-Mazovec et al., 2008). 
ROS contribute to LMP that is induced by a wide range of oxidative stimuli (e.g. drugs, heavy metals 
and ionising radiation) and conditions (e.g. ischaemia–reperfusion injury, inflammation and 
neurodegenerative disorders) (Kurz et al., 2008a). Upon oxidative stress, excess H2O2 diffuses into 
lysosomes, where it reacts with redox-active iron, resulting in the production of hydroxyl radicals in 
Fenton-type reactions (Kurz et al., 2008b). Hydroxyl radicals are highly reactive and can destabilise 
the lysosomal membrane by causing lipid peroxidation and damaging lysosomal membrane proteins. 
Additionally, ROS might contribute to LMP by activating lysosomal Ca2+ channels or altering the 
activity of lysosomal enzymes such as phospholipase A2 (PLA2) (Sumoza-Toledo et al., 2011). Not 
all lysosomes are permeabilised at the same time following lethal stimuli, however the reason for this 
heterogeneity remains unclear. The production of intracellular ROS, which have a spatially limited 
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range of activity, may induce the permeabilisation of lysosomes only in those subcellular regions that 
are near to mitochondria, the major ROS-generating organelles. Therefore, lysosomes that are 
localised in the proximity of uncoupled mitochondria are more likely to suffer damage to their 
membranes than distant lysosomes. Furthermore, lysosomes contain the primary reservoir of 
chelatable iron, which accumulates upon the autophagic degradation of iron-containing proteins 
including mitochondrial cytochromes and ferritin. Iron-catalysed Fenton reactions, which produce 
highly reactive pro-oxidants, thus may damage lysosomal membranes, and go on to damage proteins 
and DNA. 
 1.5  Microtubules 
 
The cytoskeleton of eukaryotic cells is made up of three principal components – microfilaments, 
intermediate filaments and microtubules. Microtubules are responsible for maintaining cell shape and 
motility, they provide platforms for intracellular transport and are involved in a variety of cellular 
processes, including the movement of organelles, secretory vesicles, and intracellular 
macromolecular assemblies such as the motor proteins dynein and kinesin (Vale, 2003). They also 
play a major role in cell division, in both mitosis and meiosis, where they are the main constituents 
of mitotic spindles, which are required for chromosomal separation and cytokinesis. 
Microtubules are filamentous, heterodimeric proteins made up of α- and β-tubulin dimers that 
polymerise to form microtubules which consist of 13 linear protofilaments around a hollow lumen 
with an approximate diameter of 24 nm (Nogales, 2000).  The protofilaments composed of head-to-
tail arrays of tubulin dimers are arranged in parallel and are therefore polar structures with two distinct 
ends: a fast-growing plus end and a slow-growing minus end, which is important in determining the 
direction of movement along microtubules. They are constantly lengthening and shortening 
throughout all phases of the cell cycle and are in a dynamic equilibrium with the pool of free soluble 
tubulin heterodimers (Desai et al., 1997). Tubulin dimers can bind two molecules of GTP – one for 
each of the of α- and β-tubulin monomers – which functions analogously to the ATP bound to actin 
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to regulate polymerisation of microfilaments. In particular, the GTP bound to β-tubulin (though not 
that bound to α-tubulin) is hydrolysed to GDP during or shortly after polymerisation. This GTP 
hydrolysis weakens the binding affinity of tubulin for adjacent molecules, thereby favouring 
depolymerisation and resulting in the dynamic behaviour of microtubules (Weisenberg et al., 1976). 
GTP hydrolysis to GDP causes a conformational change in β-tubulin subunits and places the polymer 
under conformational tension while in the microtubule lattice, but is stabilised by a “GTP cap” – a 
layer of GTP-containing subunits – at its ends, and when this is lost, rapid depolymerisation occurs 
(Mitchison et al., 1984; Nogales et al., 2003). In microtubules, GTP hydrolysis also results in the 
behaviour known as dynamic instability, in which individual microtubules alternate between cycles 
of growth and shrinkage. Whether a microtubule grows or shrinks is determined by the rate of tubulin 
addition relative to the rate of GTP hydrolysis. As long as new GTP-bound tubulin molecules are 
added more rapidly than GTP is hydrolysed, the microtubule retains a GTP cap at its plus end and 
microtubule growth continues (Figure 
3). However, if the rate of 
polymerisation slows, the GTP bound to 
tubulin at the plus end of the 
microtubule will be hydrolysed to GDP. 
If this occurs, the GDP-bound tubulin 
will dissociate, resulting in rapid 
depolymerisation and shrinkage of the 
microtubule (Desai et al., 1997). 
1.5.1  Microtubule Targeting Agents 
Because microtubules are implicated in such key cellular activities as mentioned previously, 
compounds that interfere with microtubule cytoskeleton functions have been developed as cytotoxic 
agents, not only for basic research experiments to demonstrate the dependence of cellular processes 




on microtubules, but most importantly to combat parasites and cancer, and have been in clinical 
practice for decades (Jordan et al., 2004). Not long after the discovery of microtubules in the late 
1950s by transmission electron microscopy and identification in the early 60s (Slautterback, 1963; 
Brinkley, 1997), the drug colchicine – commonly used to treat gout – was identified as the first 
microtubule targeting agent (MTA) and found that it bound to tubulin, at what is now called the 
colchicine-binding site (Borisy et al., 1967a; Borisy et al., 1967b). Since then a variety of MTAs have 
been developed, with the majority being natural products or synthetic derivatives thereof that 
originate from natural sources such as marine sponges, plants or bacteria. These can be broadly 
categorised into two classes, microtubule-stabilising agents (MSAs) and microtubule-destabilising 
agents (MDAs). Arguably the most famous of MTAs is paclitaxel (Taxol), a gold-standard of 
chemotherapeutics, first isolated from the Pacific yew tree in 1971 and approved in 1992 where it 
became a first-line treatment for ovarian, breast, bladder, prostate and lung cancers (Wani et al., 1971; 
Jordan et al., 2004; Yang et al., 2017). 
MTAs have largely been successful in clinical use, due to their novel mechanism of action. 
Microtubules are present in both interphase cells and dividing cells; in the latter, microtubules 
constituting the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors. 
Therefore, in rapidly dividing cells, such as with cancer, MTAs are seen to have a profound effect. 
However, in addition to massive success in the clinic, the application of MTAs is hampered by 
toxicity and the development of resistance (Kavallaris, 2010; Miltenburg et al., 2014). Similar to 
other chemotherapeutics, MTAs such as taxanes and the vinca alkaloids are hindered by peripheral 
neuropathy, a potentially dose limiting side effect where these agents are suggested to damage axons 
and neuronal bodies. Resistance to these drugs also provides a major obstacle to overcome, as 
multidrug resistance (MDR) results in the loss of activity of anticancer agents against cells possessing 
the MDR phenotype. The two mechanisms most commonly associated with the development of MDR 
are the overexpression of members of the ATP-binding cassette family of transporters, of which P-
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glycoprotein is the best known, and mutations in the structure of tubulin, which directly affects the 
binding and efficacy of most MTAs (Fojo et al., 2005; Kavallaris, 2010). 
To overcome these challenges additional chemotherapeutic MTAs such as epothilone (Ixempra®), 
eribulin (Halaven®), auristatin (Adcetris®), and maytansine (Kadcyla®) have been approved by the 
FDA in the past 10 years and introduced into the clinic either as classical drugs or as antibody–drug 
conjugates (ADCs). Numerous compounds are also under investigation which supposedly act upon 
microtubules through novel mechanisms, as well as an ongoing effort in repurposing already 
approved drugs not initially indicated for cancer treatment, such as in the case of the compounds 
involved in this thesis (Nathwani et al., 2009; Pantziarka et al., 2014; Medellin et al., 2016). 
 
1.5.2  Microtubule Stabilising and Destabilising Agents 
MTAs are generally categorised into two major groups – MSAs and MDAs – based upon their effects 
at high concentrations on microtubule polymer mass. Colchicine-site ligands are probably the most 
extensively studied class of MTAs and promote the destabilisation of tubulin by binding to the 
colchicine site, which is a deep pocket buried in the intermediate domain of β-tubulin, located near 
the intra-dimer interface between the α- and β-tubulin subunits (Ravelli et al., 2004; Dorléans et al., 
2009). In the course of microtubule assembly, tubulin dimers undergo conformational changes from 
a ‘curved’ conformation in their free state to a ‘straight’ structure in microtubules, which is 
accompanied by a contraction of the colchicine site (Akhmanova et al., 2015). Thus, binding of a 
ligand to the colchicine site inhibits microtubule formation mainly by preventing the curved-to-
straight conformational change in tubulin. Vinca-site ligands are another major class of MDAs, with 
the vinca alkaloids representing the oldest family of compounds that target this site. Vinblastine and 
vincristine have received extensive clinical evaluation and have proved effective against a variety of 
malignancies (Johnson et al., 1963). The vinca site-targeting agents known to date comprise several 
chemical classes of compounds of both natural and synthetic origin, such as the highly potent 
cytotoxic peptides dolastatins, auristatins, and tubulysins which are used as payloads for ADCs, as 
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well as eribulin, diazonamides, and triazolopyrimidines (Steinmetz et al., 2018). Ligands targeting 
the vinca site bind at the inter-dimer interface between two longitudinally aligned tubulin dimers. 
Microtubule destabilisation by vinca-site ligands is achieved either by introducing a molecular 
‘wedge’ at the tip of microtubules, which prevents the curved-to-straight transition of tubulin 
necessary for proper incorporation into microtubules, or by sequestering tubulin dimers into ring-like 
oligomers that are incompatible with the straight protofilament structure in microtubules. Ligand 
binding further inhibits proper positioning of the catalytic α-tubulin residues that promote GTP-
hydrolysis on β-tubulin (Gigant et al., 2005; Ranaivoson et al., 2012). 
Unlike MDAs, MSAs interact with microtubules by rather enhancing polymerisation and stabilising 
microtubule formation. Paclitaxel, as mentioned previously, is a historic chemotherapeutic agent, and 
falls into this class of MTAs. Paclitaxel, along with other MSAs such as epothilone, zampanolide, 
discordermolide, taccalonolide and other taxanes, all show high affinity for the taxane binding region, 
which is located in the lumen of microtubules, whereas other more recently discovered marine MSAs 
such as laulimalide and peloruside A bind to a site on β-tubulin, distinct from the taxane site, located 
on the outside of the microtubule (Prota et al., 2014; Kellogg et al., 2017). Paclitaxel binds to the 
taxane region on GDP-bound β-tubulin in the microtubule lumen, and reduces strain from curvature 
by strengthening longitudinal tubulin contacts via an allosteric mechanism, leading to the favoured 
straightened conformation and increased intracellular concentration of the polymerised protein (Elie-
Caille et al., 2007; Alushin et al., 2014). 
1.6  Drug Repurposing 
In the context of cancer, the tubulin family of proteins is recognised as the target of the tubulin-
binding chemotherapeutics or MTAs, which suppress the dynamics of the mitotic spindle to cause 
mitotic arrest and cell death. Importantly, changes in microtubule stability and the expression of 
different tubulin isotypes as well as altered post-translational modifications have been reported for a 
range of cancers. These changes have been correlated with poor prognosis and chemotherapy 
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resistance in solid and haematological cancers (Kavallaris et al., 2001; Sale et al., 2002; Martello et 
al., 2003; Verdier-Pinard et al., 2003; Mozzetti et al., 2005). However, the mechanisms underlying 
these observations have remained poorly understood. Emerging evidence suggests that tubulins and 
microtubule-associated proteins may play a role in a range of cellular stress responses, thus conferring 
survival advantage to cancer cells. This opens the door for new potential drug candidates that may be 
either novel compounds or repurposed from another indication, and may potentially act through a 
new mechanism of action or binding site and/or ability to avoid resistance. Currently, the method of 
obtaining new drugs is a long and expensive process involving drug-screening, a range of in vitro and 
pre-clinical work all the way up to clinical trials and drug approval. However, a solution to this is the 
Repurposing Drugs in Oncology (ReDO) Project, which seeks to repurpose well-known and well-
characterised non-cancer drugs for new uses in oncology. Interest in oncological drug repurposing 
(also sometimes called drug repositioning) is driven by a range of concerns: productivity issues in 
current drug development; the need to address existing unmet patient needs; and the economic impact 
of existing and projected cancer incidence on health systems in both advanced and developing 
countries. A recent analysis has shown that the number of new drugs approved per billion US dollars 
spent on research and development has halved every nine years since 1950, falling around 80-fold in 
inflation-adjusted terms (Scannell et al., 2012). The crisis is particularly acute in oncology, where the 
success rate for new drugs from Phase I trial to US Food and Drug Administration (FDA) approval 
in the period 2003 to 2011 was around 6.7%, a figure that is about half the rate for non-oncological 
drugs (Hay et al., 2014). In contrast to the de novo development of new molecules, drug repurposing 
begins with known pharmaceutical agents with a history of clinical use. There is, therefore, a wealth 
of data that is accessible to the clinician and researcher, including published data on 
pharmacokinetics, bioavailability, toxicities (common and uncommon), established protocols, and 
dosing. This is data that is far in excess of what can be derived from Phase I clinical trials of new 
drugs, particularly for first in class drugs. In one review of drug repositioning versus de novo drug 
development, a 10–17 year development lifecycle for de novo development is contrasted with a 3–12 
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year process for repurposed drugs (Ashburn et al., 2004). One of the aims of the ReDO project is to 
further truncate this development time. Currently, the first six drugs that are part of the ReDO project 
include: mebendazole, nitroglycerin, cimetidine, clarithromycin, diclofenac and itraconazole 
(Pantziarka et al., 2014). 
1.7 Study Compounds 
 
Recently, anithiactin A, a bacterial secondary metabolite, was isolated from Streptomyces sp., found 
in a sample of intertidal mudflat sediment collected on the southern coast of the Korean peninsula 
(Kim et al., 2014). At approximately the same time, a separate research group isolated the same 
compound from marine-derived Actinomycetospora chlora SNC-032 from a mangrove swamp in 
Tonga and named it thiasporine C (Fu et al., 2015). Anithiactin A/thiasporine C contains a 2-
phenylthiazole core which has previously been shown to be a useful scaffold in the design of 
compounds with anti-cancer properties (Gududuru et al., 2005). In particular, methoxybenzoyl 
phenylthiazoles have been shown to possess low nanomolar activity with selectivity for both 
melanoma and prostate cancer cell lines and preliminary investigations on their mode of action 
suggests they operate via inhibition of tubulin polymerisation (Lu et al., 2009). The Hawkins Lab 
group from the Department of Chemistry, University of Otago, were interested in the structure of this 
compound and developed an original synthesis to produce anithiactin A/thiasporine C along with a 
range of novel structural analogues. Although anithiactin A/thiasporine C previously displayed no 
significant biological activity against a range of non-small-cell lung cancer cell lines, two structural 
analogues 4-thiazolecarboxylic acid, 4, 5-dihydro-2-(4-nitrophenyl)-methyl ester (D1 (11c – Lamb et 
al. paper)) and 4-thiazolecarboxylic acid, 2-(4-nitrophenyl) -methyl ester (D2 (12c – Lamb et al. 
paper)), with nitro groups substituted at the 4-position on the phenyl ring (Figure 4), were observed 
to significantly decrease cell viability of breast and colon cancer cells over 24-72 hrs in the 
micromolar range (Lamb et al., 2015). Following these findings, the investigation of the mechanism 







The novel compounds D1 and D2 were the primary focus of this investigation however, over a period 
of months and with a newly synthesised batch of compounds, D1 and D2 lost their biological activity 
most likely due to degradation in solution and two new compounds were then selected for 
investigation based upon a similar MOA involving tubulin interaction. Mebendazole (MBZ) and 
albendazole (ABZ) are broad-spectrum benzimidazole anti-helminthic drugs, in the same class as 
thiabendazole, flubendazole, oxfendazole, and others (Figure 5). They are commonly prescribed to 
treat a range of parasitical worm infections, including threadworm, tapeworms, roundworms, and 
other nematode and trematode infections in humans and domestic animals. MBZ is available as a 
generic drug: common trade names have included Vermox (Janssen Pharamceutica) and Ovex 
(McNeil Products Ltd) in the US and Europe. MBZ is one of the primary drug candidates of the ReDO 
Project (Repurposing Drugs in Oncology), aiming to reposition already approved drugs with known 
safety profiles, for new indications in cancer treatment (Pantziarka et al., 2017). MBZ has recently 
been shown to have promising anticancer effects in a range of pre-clinical in vitro and in vivo studies 
(Mukhopadhyay et al., 2002; Sasaki et al., 2002; Martarelli et al., 2008), with albendazole also 
showing potent anti-tumour properties in vivo (Castro et al., 2016). Although the anti-helminthic 
mechanism of action is well understood and involves the inhibition of tubulin polymerisation, leading 
to reduced glucose uptake in gastrointestinal cells of helminths, the mechanism of action leading to 
cytotoxicity in cancer cells, particularly in breast and colorectal cancers, remains to be fully explored. 
 







1.8 Aims and Hypothesis 
The aim of this study was to identify the in vitro anticancer mechanism of action of the novel 
substituted phenylthiazoles D1 and D2, as well as the antihelminthic benzimidazoles MBZ and ABZ. 
This would be carried out by first screening the drugs for cytotoxicity in three cancer cell lines and 
one non-cancerous mesenchymal stem cell line. Then using an array of in vitro assays, flow cytometry 
and fluorescent microscopy to observe changes in apoptotic or necrotic markers and interaction with 
microtubules and their involvement in cell death. 
It is hypothesised that MBZ and ABZ will produce cell death in cancer cells via apoptosis, and in a 









Figure 5: Chemical structures of mebendazole (MBZ) and albendazole (ABZ). 
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Chapter 2:  Materials and Methods 
2.1 Materials 
 
Dimethyl sulfoxide (DMSO) was purchased from Scharlau (Barcelona, Spain). Fetal Bovine Serum 
(FBS), Penicillin Streptomycin (PS), PBS (8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4; 
pH 8.0) and Trypsin (2.69 mM EDTA, 1 g/L trypsin, 0.14 M NaCl, 76.78 mM Tris HCl; pH 8.0) were 
purchased from Gibco (Carlsbad, CA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT), Acridine Orange (A6014), DTNB (D8130), Propidium Iodide (PI) (P4170) and 
RNAse A (R6513) were purchased from Sigma-Aldrich (St. Louis, MO). Annexin V-FITC 
(OPSB00049), Ac-DEVD-AMC (14986) and z-VAD-FMK (AB120382) were purchased from 
Sapphire Biosciences (NSW, Australia). Hoechst 33342 (Excitation/Emission 352 nm/461 nm) and 
TMRE (T669) were purchased from Life Technologies (California, USA). α-tubulin (DM1A) Mouse 
mAB, Acetyl-α-tubulin (Lys40) (D20G3) XP® Rabbit mAB, Anti-rabbit IgG (H+L), F(ab’)2 
Fragment (Alexa Fluor® 488 Conjugate) and Anti-mouse IgG (F(ab’)2 Fragment (Alexa Fluor® 594 
Conjugate) were all purchased from Cell Signaling Technology (MA, U.S.A). MCF-7 and MDA-
MB-231 breast cancer cell lines were kindly gifted from Professor Rhonda Rosengren (University of 
Otago). HT-29 colorectal cancer cell line was purchased from ATCC (HTB-38). RCB2157 
mesenchymal stem-cell line were obtained from the Riken BioResource Centre through the National 
Bio-resource Project of the MEXT, Japan. 
2.2  Treatment Compounds 
 
D1 (4-Thiazolecarboxylic acid, 4,5-dihydro-2-(4-nitrophenyl)-methyl ester) and D2 ( 4-
Thiazolecarboxylic acid, 2-(4-nitrophenyl)-methyl ester) were obtained from the Department of 
Chemistry, University of Otago, where they were synthesised by the Hawkins’ lab group and given 
at 10 mM dissolved in DMSO, stored in the dark at room temperature. Mebendazole ≥98% and 
Albendazole ≥98% were purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in DMSO at 
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5 mM stock concentrations, stored at 4oC in the dark. Paclitaxel ≥98% was purchased from Cayman 
Chemical (Michigan, U.S.A) and dissolved in DMSO at a stock concentration of 1 mM also stored at 
4oC in the dark. DMSO was therefore used as a vehicle control for all experiments and treated at 0.1% 
v/v which was deemed to be non-toxic to all cell lines. 
2.3  Cell Culture  
 
Three human cancer cell lines were used in experiments and included; MCF-7 – breast 
adenocarcinoma, MDA-MB-231 – triple negative breast cancer, and HT-29 – colorectal 
adenocarcinoma. The non-cancerous, human bone marrow mesenchymal stem cell (MSC) line 
RCB2157 was also used. All cell lines were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) with 5% heat inactivated fetal bovine serum (FBS)/10% for MSCs, 100 units/mL penicillin 
and 100 µg/mL streptomycin, in Corning T75 flasks. Cells were incubated at 37oC in humidified 
conditions with 5% CO2. At 90% confluency, cells were passaged by the addition of 2 mL trypsin 
solution (2.69 mM EDTA, 1 g/L trypsin, 0.14 M NaCl, 76.78 mM Tris HCl; pH 8.0) followed by a 
2-min incubation at 37°C, to allow cells to detach from the bottom of the flask. Cells were rescued 
using fresh supplemented growth medium (10 mL). Cell-trypsin-medium solution was centrifuged at 
1200 rpm for 3 min at 4°C. Supernatant was removed, and cells were resuspended in supplemented 
DMEM 5% FBS medium (20 mL).  
2.4  MTT Assay 
 
Cells were seeded onto 96-well plates at 5000 cells/well. The quantity of live cells present following 
24 and 48hr treatment exposure was measured. Treatments with D1, D2, MBZ, ABZ, paclitaxel, 
DMSO (vehicle control) or untreated control were compared using the MTT assay, which assesses 
mitochondrial and endoplasmic reticulum dehydrogenase activity. Live cells lead to the formation of 
purple formazan crystals which can be further quantified (Mosmann, 1983; Sylvester, 2011). Cells 
were treated with 50 µM of D1 and D2 (dissolved in serum-free media), as a previous study had found 
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the IC50 of these compounds to be approximately 50-100 µM (Lamb R, 2015). DMSO was used as a 
vehicle control (0.1% v/v). MTT was made up to 5 mg/mL in phosphate buffered saline (PBS), added 
to cells at a final concentration of 0.5 mg/mL, and incubated at 37oC for 3 hrs following treatment 
exposure. Media was then aspirated and the formazan crystals were then dissolved with DMSO, and 
the resulting absorbance was read at 560 nm using the Bio Rad Benchmark Plus microplate 
spectrophotometer. Three individual experiments were carried out with four replicate wells for each 
treatment. 
 
2.5 Caspase-3 Assay 
HT-29 cells were plated at 300,000 cells/well and treated for 24 hrs with MBZ (2 µM), ABZ (2 µM), 
paclitaxel (50 nM), DMSO 0.1% v/v or left untreated. Cells were harvested and frozen in -80OC for 
a minimum of 24 hrs. Samples were then suspending in 1mL of caspase buffer (100 mM HEPES pH 
7.25; 10% sucrose; 0.1% CHAPS; 0.0001% NP-40), with 5 µL of DTT (1 M) and 3.4 µL of the 
caspase-3 substrate Acetyl-DEVD-AMC (50 mM, dissolved in DMSO). Following 1 hr of incubation 
at 37OC the fluorescent intensity was measured using a fluorescent spectrophotometer with 10 mm 
excitation and emission slits, with the excitation wavelength set at 380 nm and emission wavelength 
400-600 nm. 
2.6 Flow Cytometry 
 
Flow cytometry was carried out using a BD FACSCantoII® flow cytometer and data analysed using 
FlowJo® VX software. Cells were seeded in 6-well plates at 300,000 cells/well in 5% FBS DMEM 
and left to adhere for 24 hrs. Where indicated in their respective figure legends, cells were then treated 
with 50 µM D1, D2, 2 µM MBZ, ABZ, 50 nM paclitaxel or DMSO (0.1% v/v), or left as untreated 
control. After either 24 or 48 hrs, cells were then stained with propidium iodide (PI) alone, annexin 
V/PI, acridine orange (AO) or tetramethylrhodamine ester (TMRE) and analysed using the 
appropriate filters FITC and/or PE. Three separate experiments were carried out for each stain, where 
each individual experiment analysed 150,000 stopping events (cells) per treatment sample. 
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2.6.1  Apoptosis/Necrosis 
 
Annexin V/PI double stain is a common method used to determine if cells are viable, apoptotic, or 
necrotic through differences in plasma membrane integrity and permeability (Vermes et al., 1995; 
Rieger et al., 2011). The ability of PI to enter a cell is dependent upon the permeability of the 
membrane: PI does not stain live or early apoptotic cells due to the presence of an intact plasma 
membrane. In late apoptotic and necrotic cells, the integrity of the plasma and nuclear membranes 
decrease, allowing PI to pass through the membranes, intercalate into nucleic acids, and display red 
fluorescence. Annexin V cannot cross the plasma membrane either however, it binds to externalised 
phosphatidylserine residues, which commonly occurs during apoptosis, and displays green 
fluorescence due to conjugation with the dye FITC (Vermes et al., 1995). Therefore, using these two 
stains in conjunction, it can be determined whether cells are viable, apoptotic, or necrotic, based on 
the intensity of the fluorescence of the stains. 
 
Following incubation with respective treatments for 24 or 48 hrs, media from each well was collected 
into labelled tubes and the wells then washed with PBS. Cells were then harvested using 200 µL 
trypsin per well and incubated at 37oC for 2 mins, where the cell suspension was then collected by 
adding 1 mL of 5% DMEM and centrifuged at 4oC, 2000 rpm for 3 mins. The supernatant was aspirated 
and the pellet was washed twice in 1 mL of 4oC PBS and centrifuged. Following this, the supernatant was 
aspirated and the cells resuspended in 100 μL of Annexin V binding buffer (HEPES; 10.0 mM (pH 7.4), 
NaCl; 140.0 mM, and CaCl2; 2.5 mM) supplemented with 5 μL of PI (10 μg/mL) and 5 μL of annexin V 
conjugated to FITC. The cells were incubated for 15 min in the dark at room temperature before the cells 
were resuspended in an additional 300 µL of FACS binding buffer. 
Compensation controls were carried out using single-stained Annexin V and single-stained PI 
samples. Data were analysed using FlowJo® VX software. Cellular debris was gated out using a dot-
plot with FSC-A and SSC-A parameters and apoptosis/necrosis or viable cells determined using a 
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quadrant gate separating cell populations that are Annexin+/PI-, Annexin+/PI+, Annexin-/PI+, and 
Annexin-/PI- based upon fluorescence intensity, using the compensated FITC and PE channels. 
2.6.2  Cell Cycle 
 
As PI binds to DNA stoichiometrically, it can be used in conjunction with flow cytometry to 
determine cell cycle (Pozarowski et al., 2004). 
Following incubation with respective treatments for 24 or 48 hrs, media from each well was collected 
into labelled tubes and the wells then washed with PBS. Cells were then harvested using 200 µL 
trypsin per well and incubated at 37oC for 2 mins, where the cell suspension was then collected by 
adding 1 mL of 5% DMEM and centrifuged at 4oC, 2000 rpm for 3 mins. The supernatant was aspirated 
and the pellet was washed twice in 1 mL of 4oC PBS and centrifuged. As PI is impermeable to intact 
cell membranes, cells were first fixed with 70% ethanol dropwise (500 µL) to allow permeabilisation 
of the plasma membrane, and left at 4oC for a minimum of 30 mins. Cell were then washed twice in 
phosphate-citrate buffer (Na2HPO4; 192 mM, Citric acid; 4 mM (pH 7.8)) and centrifuged at 4oC, 
2000 rpm for 3 mins. Supernatant was discarded and cells then treated with 50 µL of 100 µg/mL 
RNAse A to remove potential binding between PI and RNA. Three hundred µL of 50 µg/mL of PI 
was then added to each sample. Following PI treatment, cells were analysed following flow cytometry 
using FlowJo® VX software, where cell cycle is measured from a histogram of PI fluorescence using 
the PE channel. Cellular debris was initially gated out using a dot-plot with FSC-A and SSC-A 
parameters. Using a linear scale, the G2 peak should be double the intensity of the G1 peak due to 
double the amount of DNA present in those cells (2n). From here gates were applied manually or 
through the separate cell cycle function where available. Cells were not synchronised before treatment 
2.6.3  Mitochondrial Membrane Integrity 
 
Mitochondrial dysfunction has been shown to be part of the induction of apoptosis and has been 
suggested to be central to the apoptotic pathway (Ly et al., 2003). The opening of the mitochondrial 
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permeability transition pore has been demonstrated to induce depolarisation of the transmembrane 
potential (Δψm), release of apoptogenic factors such as cytochrome c and loss of oxidative 
phosphorylation. In some apoptotic systems, loss of Δψm can be an early event in the apoptotic 
process. TMRE is a fluorescent dye that is readily sequestered by active mitochondria, allowing for 
flow cytometric or imaging analysis to assess for apoptosis or mitochondrial depolarisation (Crowley 
et al., 2016a). Non-apoptotic or cells with polarised mitochondria will fluoresce red while apoptotic 
or cells with depolarised mitochondria will have diminished levels of red fluorescence, which can be 
quantified. 
Following incubation with respective treatments for 24 or 48 hrs, media from each well was collected 
into labelled tubes and the wells then washed with PBS. Cells were then harvested using trypsin and 
incubation at 37oC for 2 mins, when the cell suspension was then collected by adding 5% DMEM 
and centrifuged at 4oC, 2000 rpm for 3 mins. Cells were resuspended in 5% DMEM and TMRE was 
added to give a final concentration of 40 nM, followed by incubation at 37oC for 10 mins. Cells were 
then centrifuged and washed in PBS then resuspended in 5% DMEM. 
Following flow cytometry, using FlowJo® VX, cellular debris was initially gated out using a dot-plot 
with FSC-A and SSC-A parameters. Then, using a histogram vs PE on a logarithmic scale and a gate 
to the left of the high-intensity peak seen in untreated control samples, the percentage of cells with 




2.6.4 Lysosome Membrane Integrity 
Lysosomal membrane permeabilisation (LMP) and the consequent leakage of the lysosomal content 
into the cytosol leads to so-called “lysosomal cell death” (Boya et al., 2008b; Aits et al., 2013a; 
Repnik et al., 2014). This form of cell death is mainly carried out by the lysosomal cathepsin proteases 
and can have necrotic, apoptotic or apoptosis-like features depending on the extent of the leakage and 
the cellular context. LMP can be induced by a wide range of pharmacological agents and endogenous 
factors, such as reactive oxygen species and cell death effectors such as Bax (Boya et al., 2008b). 
Acridine orange (AO) is a lipophilic amine that readily diffuses into cells. Inside the cell it enters the 
acidic lysosomal compartment where it is protonated and sequestered, shifting its emission spectrum 
towards a longer wavelength that is red (Moriyama et al., 1982). Once inside the lysosomes, the 
metachromatic AO sensitises the lysosomal membrane to photo-oxidation by blue light (Brunk et al., 
1997). Upon light-induced loss of the lysosomal pH gradient and subsequent leakage of AO into the 
cytosol, the emission spectrum of AO shifts from red to green, where there is a decrease in intensity 
of red fluorescence which can be quantified, much like TMRE and the depolarisation of the 
mitochondrial membrane potential. 
Figure 6: An example of a histogram measuring 
depolarised/permeabilised mitochondria. Flow cytometry 
histogram of Jurkat cells stained with TMRE with (blue) or 
without (red) treatment with 100µM FCCP, an ionophore 
uncoupler of oxidative phosphorylation. Treating cells with 
FCCP eliminates mitochondrial membrane potential and 
TMRE staining. (From Abcam® TMRE-Mitochondrial 
Membrane Potential Assay Kit ab113852 product datasheet) 
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Following incubation with respective treatments for 24 or 48 hrs. AO was added to each well giving 
a final concentration of 4 µg/mL and incubated in the dark at 37oC for 15 mins. Supernatants were 
then collected and cells washed with PBS before being harvested with trypsin. Cells and supernatants 
were centrifuged at 4oC, 2000 rpm for 3 mins, washed with PBS then resuspended in 5% DMEM. 
Following flow cytometry, using FlowJo® VX, cellular debris was initially gated out using a dot-plot 
with FSC-A and SSC-A parameters. Then, using a histogram vs PE or vs FITC on a logarithmic scale 
and a gate to the left of the high-intensity peak seen in untreated control samples, the percentage of 
cells with low-intensity fluorescence, indicating compromised lysosomal or outer membrane were 
measured, similar to the TMRE stain (Figure 6). 
2.7  DTNB Assay (Free Sulfhydryl Content) 
Free sulfhydryl content following treatment was assessed using the DTNB (5, 5”-dithio-bis-(2-
nitrobenzoic acid)) assay. DTNB is a versatile, water-soluble compound that can quantify free 
sulfhydryl groups in solution by reacting with them and producing a measurable yellow-coloured 
product (Ellman, 1959). Using the molar extinction coefficient of 14,150 M-1 cm-1 and the absorbance 
measured by a spectrophotometer, the free sulfhydryl content can be calculated. 
Cells were plated in 6-well plates at 300,000 cells/well and left to adhere for 24 hrs. Cells were then 
treated with DMSO 0.1% v/v, D2 50 µM, MBZ 2 µM, ABZ 2 µM, paclitaxel 50 nM or were untreated 
and were incubated at 37oC for 48 hrs. Following treatment, media from each well was collected into 
labelled tubes and the wells then washed with PBS. Cells were then harvested using 200 µL trypsin 
per well and incubated at 37oC for 2 mins, where the cell suspension was then collected by adding 1 
mL of 5% DMEM and centrifuged at 4oC, 2000 rpm for 3 mins and washed with PBS twice. Cells 
were resuspended in 1 mL of PBS and sonicated for 2 mins. Five hundred µL of 10% SDS and DTNB 
at a final concentration of 30 µM were added and incubated at room temperature for 30 mins. Samples 
were then placed in 1 mL cuvettes and absorbance measured at 412 nm using a spectrophotometer. 
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2.8 Fluorescent Microscopy 
Cells were plated in 8-well microscope slides at approximately 25,000 cells per well. They were 
treated with D2 (50 µM), MBZ (2 µM), ABZ (2 µM), paclitaxel (50 nM), DMSO (0.1% v/v) and 
untreated control for 48 hrs. Following treatment, the media from the wells were aspirated and cells 
fixed with 4% paraformaldehyde (pH 7.2) and washed three times with PBS. They were then stained 
with the DNA-selective dye Hoechst 33342 at 10 µg/mL to analyse the nuclear morphology of the 
cells, as nuclear/chromatin condensation (pyknosis) and blebbing are indicative of apoptosis. 
Following washing with distilled water, the slides were dried and Prolong Gold was placed on the 
slides along with coverslips. The cells were then analysed using the Nikon AI-R inverted fluorescent 
microscope with Nikon Intensilight C-HGFI mercury lamp (Olympus, Japan) at 20x magnification. 
For tubulin staining, the steps above were repeated with MBZ (2 µM), ABZ (2 µM), paclitaxel (50 
nM), DMSO (0.1% v/v) treatments for 8 hrs. Following fixation cells were first blocked for 60 mins 
using blocking buffer (1X PBS; 5% BSA; 0.3% Triton X-100). Then stained with a primary antibody 
solution containing (1X PBS; 5% BSA; 0.3% Triton X-100; anti-α-tubulin – 1;16,000; anti-acetyl-α-
tubulin – 1:800) overnight at 4oC. Following washing cells were then incubated with respective 
secondary anti-mouse and anti-rabbit antibodies, in conjunction with Hoechst 33342 at 10 µg/mL for 
1 hr at room temperature in the dark. Coverslips were placed along with Prolog Gold antifade reagent 
and left to cure overnight. Photos were then taken using the Nikon AI-R inverted fluorescent 
microscope with Nikon Intensilight C-HGFI mercury lamp (Olympus, Japan) at 20x magnification 
using consistent exposure. Images were then analysed using Fiji Image J software. 
2.9  Statistical Analyses 
All results were analysed using GraphPad Prism® 6.0 software. Cell viability experiments contained 
four replicates for each treatment, however this is a form of pseudoreplication (Lazic, 2010) and only 
represents n=1, therefore a minimum of three separate experiment each with four pseudoreplicates 
were carried out to give n=3. Flow cytometry experiments were similar in that each sample was 
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measured at least three times for each treatment, again pseudoreplication, however, three separate 
experiments were carried out to give n=3. All data from both cell viability, flow cytometry and DTNB 
assay experiments were analysed using one-way analysis of variance (ANOVA). ANOVAs were used 
as there were more than two treatment groups in each experiment, where the samples were 
independent and only one variable was measured. Dunnett’s post hoc tests were used in conjunction 










Chapter 3:  D1 and D2 Results 
 
3.1 Caspase Inhibition  
To determine whether caspases played a role in the mechanism of cell death induced by these 
substituted phenylthiazoles, the pan-caspase inhibitor z-VAD-FMK was employed, where it was used 
to see if it had any change on cell viability following drug treatment. In MCF-7 cells, the caspase 
inhibitor had no effect on cell viability alone at 0.1 and 1.0µM compared to DMSO control, D2 
treatment caused a 65% decrease in cell viability (35.6 ± 2.8% vs 100 ± 10.4%, p < 0.0001) (Figure 
7), which could not be rescued by the caspase inhibitor at either 0.1 or 1.0µM (33.1 ± 0.3%, 31.9 ± 
0.5% respectively) (p < 0.0001). Paclitaxel 100nM also decreased cell viability by 26% (p = 0.012). 
In the triple-negative breast cancer cell line MDA-MB-231, the caspase inhibitor had no effect on 
cell viability at 1.0µM, whereas at 0.1 µM it led to a small (6%) but statistically significant (p = 0.002) 
increase in cell viability compared to DMSO control. D2 and paclitaxel treatments led to significant 
decreases in cell viability (42.9 ± 0.7%, 45.2 ± 0.5% respectively) (p < 0.0001). The caspase inhibitor 
again showed no difference in cell viability in conjunction with D2 compared to D2 alone, at both 
concentrations, and gave similar cell viability results compared to DMSO control (43.1 ± 0.5% (0.1 
µM); 44.9 ± 0.8%, p < 0.0001) (Figure 7). In HT-29 cells, the caspase inhibitor alone at both 0.1 and 
1.0 µM caused statistically significant decreases in cell viability compared to DMSO control (92.6 ± 
1.7%, 87.2 ± 1.6% vs 100.0 ± 1.1% respectively, p < 0.0001). Similar to MCF-7 and MDA-MB-231 
the caspase inhibitor at both 0.1 and 1.0 µM could not rescue the decrease in cell viability seen in D2 
treatment alone, when treated together (D2 + CI 0.1 µM – 35.9 ± 0.4%; D2 + CI 1.0 µM – 35.8 
±0.4%; D2 alone – 38.8 ± 0.4%, p < 0.0001) (Figure 7). 
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Figure 7. Viability of MCF-7, MDA-MB-231 and HT-29 cells following treatment with the pan-
caspase inhibitor (CI) z-VAD-FMK (0.1, 1.0µM), D2 (50µM), D2 + CI and paclitaxel 100 nM 
compared to DMSO 0.1% v/v vehicle control, determined using MTT assays. Cells were drug treated 
for 48hr, with z-VAD-FMK exposed 30 mins prior to drug treatment. Data represents means ± SEM 
of three separate experiments performed in quadruplicate (n = 3). Data was analysed using One-way 
ANOVAs with Dunnett’s post-hoc test comparing to DMSO control, where p < 0.05 was considered 




3.2  Cell Cycle 
Cell cycle analysis was carried out in cells treated with D1, D2, DMSO or untreated for 48 hrs using 
propidium iodide staining and flow cytometry to quantify DNA content. There were no significant 
changes in percentages of cells in each cell cycle stage following treatments with either DMSO, D1 
or D2 compared to control (p > 0.05) in MCF-7 cells (Figure 8). 
 In MDA-MB-231 cells the only statistically significant difference observed was an approximate 5% 
decrease in the percentage of cells in the G1 phase following D1 treatment compared to control 
(52.85% vs 48.04%, p = 0.016) (Figure 8). 
HT-29 cells also showed statistically significant changes compared to control following D1 treatment. 
Percentage of cells in the G1 stage were increased by 7.5% (51.83% vs 59.42%, p = 0.002), which 
subsequently led to a 5.6% decrease in the percentage of cells in the S phase (24.01% vs 18.40%, p 
= 0.026) (Figure 8). 
 
3.3  Mitochondrial Membrane Potential (ΔΨm) 
Cells were treated with D1, D2, DMSO or untreated control for 48hrs and their mitochondrial 
membrane potential (Δψm) assessed using flow cytometry with the fluorescent dye TMRE, which is 
sequestered by active mitochondria producing high fluorescence intensity. All three cell lines 
displayed no change in percentage of cells with depolarised mitochondrial membrane potential 
compared to control (MCF-7 – 2.00 ± 0.17 %; MDA-MB-231 – 9.01 ± 2.43%; HT-29 – 5.70 ± 1.73%) 
following treatments with DMSO 0.1%, D1 50µM or D2 50µM (p > 0.05) (Figure 9) 
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Figure 8: Cell cycle analysis of MCF-7, MDA-MB-231 and HT-29 cells following 48hr treatment 
with D1 (50µM), D2 (50µM), DMSO (0.1% v/v) or untreated control. DNA content was assessed 
using PI staining. Data represent mean ± SEM of the percentage of cells at each cell cycle stage (Sub-
G1; G1; S; G2/M; >G2/M). Three independent experiments were conducted in triplicate with a 
minimum of 10,000 stopping events for each sample. Data were analysed using a Two-way ANOVA 
with Dunnett’s post-hoc test comparing to untreated control, where p < 0.05 was considered 






Figure 9: Percentage of cells (MCF-7, MDA-MB-231, HT-29) with depolarised mitochondrial 
membrane potential (Ψ) determined by TMRE fluorescence intensity, following 48hr treatment with 
D1 (50µM), D2 (50µM), DMSO (0.1% v/v) or untreated control. Data represent means ± SEM, of 
three separate experiments (n = 3) performed in triplicate, where each sample includes a minimum of 
10,000 stopping events. One-way ANOVAs were performed, with Dunnett’s post-hoc test where p < 
0.05 was considered as statistically significant. 
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3.4  Lysosomal Membrane Permeabilisation 
To determine whether lysosomal membrane permeabilisation was involved in the mechanism of 
action of D1 and D2, cells were treated for 48hrs with D1 and D2 (50µM) then exposed to acridine 
orange and using flow cytometry the percentage of cells with permeabilised lysosome membranes 
were measured. In MCF-7 and HT-29 cells there were no statistically significant differences in the 
percentage of cell with lysosomal membrane permeabilisation following treatments with either 
DMSO, D1 or D2 compared to control (p > 0.05) (Figure 10.). Whereas the MDA-MB-231 cell line 
displayed a 0.8% decrease following treatment with D2 compared to control (1.94 ± 0.16% vs 1.14 ± 
0.10%, p = 0.012) (Figure 10.).  
 
3.5  Nuclear Staining 
Cells were stained with Hoechst 33342 following drug treatment and nuclear morphology was 
examined using fluorescent microscopy. MCF-7 cells showed no obvious changes in nuclear 
morphology following treatment with DMSO and D2 compared to untreated control, whereas D1 
treatment displayed some cells with shrinking nuclei (pyknosis) with a greater fluorescent intensity 
(Figure 11). MDA-MB-231 cells provided difficulty in determining whether drug treatment had any 
effect on nuclear morphology as in all three treatment groups as well in untreated control there were 
cells with variable nuclei shape, size and fluorescent intensity. Therefore, it could not be concluded 
that D1 or D2 treatment had any effect on nuclei morphology. In HT-29 cells, D1, D2 and DMSO 










Figure 10. Percentage of cells (MCF-7, MDA-MB-231, HT-29) with lysosomal membrane 
permeabilisation (LMP) determined by acridine orange fluorescence intensity using flow cytometry, 
following 48hr treatment with D1 (50µM), D2 (50µM), DMSO (0.1% v/v) or untreated control. Data 
represent means ± SEM, of three separate experiments (n = 3) performed in triplicate, where each 
sample includes a minimum of 10,000 stopping events. One-way ANOVAs were performed, with 
Dunnett’s post-hoc test comparing to untreated control, where p < 0.05 was considered as statistically 
significant. 
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Figure 11. Nuclear morphology of MCF-7, MDA-MB-231 and HT-29 cells stained with Hoechst 
33342 and imaged using fluorescence microscopy. Cells were plated in 8-well microscope slides at 
approximately 25,000 cells per well. They were treated with D1, D2 (80 µM), DMSO 0.1% v/v and 
untreated control for 48 hrs. 
 
3.6  D1 and D2 Cell Viability 
D1 and D2 cell viability was determined in three cancer cell lines and one non-transformed cell line 
using the MTT assay, where live cells were quantified by functioning mitochondrial oxidoreductase 
enzymes to reduce MTT to measurable formazan crystals. The IC50 values for D1 and D2 after 24hr 
exposure were; 536.7 µM and 66.3 µM for MCF-7; 393.8 µM and 137.3 µM for MDA-MB-231; 
770.1 µM and 155.0 µM for HT-29; 603.8 µM and 1223 µM for RCB2157 respectively (Figure 12). 














Figure 12. IC50 curves of the human cancer cell lines MCF-7 (A), MDA-MB-231 (B), HT-29 (C) and 
the mesenchymal stem cell line RCB2157 (D) following 24 hr treatment with D1 and D2 (0.1-1000 
µM) compared to DMSO control, determined using MTT assays. IC50 calculated using non-linear 
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Chapter 4:  MBZ and ABZ Results 
4.1  MBZ and ABZ Cell Viability 
The IC50 values of MBZ and ABZ over 24 hrs were determined in the three cancer cell lines MCF-7, 
MDA-MB-231 and HT-29 and the non-transformed mesenchymal stem-cell line RCB2157 using 
MTT cell viability assays. Both MBZ and ABZ were observed to be the most potent in the HT-29 
cell line, giving IC50 values of 1.3 ± 0.1 µM and 1.4 ± 0.1µM respectively (Figure 13). In MCF-7 
cells, MBZ had an IC50 of 9.5 ± 1.1 µM and ABZ 50.2 ± 1.1 µM. Both MBZ and ABZ were the least 
potent in MDA-MB-231 cells of the cancer cell lines, with 31.2 ± 1.2 µM and 928.0 ± 1.6 µM 
respectively  
Figure 13.  IC50 curves of MCF-7, MDA-MB-231, HT-29 and RCB2157 cell lines following 
treatment with MBZ and ABZ (1 nM – 500 µM) for 24 hrs, compared to DMSO control, determined 
using MTT assays. IC50 values and line-of-best-fit calculated using non-linear regression. Each data 
point represents means ± SEM of three independent experiments (n = 3) carried out in quadruplicate. 





























































































H T -2 9 M S C
M D A - M B -2 3 1



































and in RCB2157 mesenchymal stem cells, with 34.8 ± 0.1 µM and 243.1 ± 0.1 µM respectively 
(Figure 13). 
The IC50 curves following 48 hr treatment with MBZ and ABZ are shown in Figure 14. HT-29 again 
was the cell line with the lowest IC50 values for both MBZ and ABZ; 0.11 ± 0.07 µM and 0.69 ± 0.42 
µM respectively. MCF-7 cells gave values of 1.1 ± 1.3 µM for MBZ and 8.1 ± 1.2 µM for ABZ. Of 
the cancer cells, MBZ and ABZ were again least potent in the MDA-MB-231 cell line with values of 
15.0 ± 0.1 µM and 53.3 ± 0.2 µM. The highest IC50 values were seen in the mesenchymal stem-cell 
line RCB2157, with 19.9 ± 0.1 µM for MBZ and 129.5 ± 0.1 µM for ABZ, suggesting that these 
drugs may be selective for cancer cells. 
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Figure 14 IC50 curves of MCF-7, MDA-MB-231, HT-29 and RCB2157 cell lines following treatment 
with MBZ and ABZ (1 nM – 500 µM) for 48 hrs, compared to DMSO control, determined using 
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MTT assays. IC50 values and line-of-best-fit calculated using non-linear regression. Each data point 
represents means ± SEM of three independent experiments (n = 3) carried out in quadruplicate. 
4.2  Caspase-3 Activity 
Caspase activity was measured in HT-29 cells following treatment using the fluorescent intensity of 
the cleaved substrate Ac-DEVD-AMC as shown in Figure 15. Both untreated control and DMSO 
vehicle control caused a peak fluorescent intensity of approximately 150 F.U (fluorescence units) at 
440 nm. ABZ treatment and MBZ treatment both increased fluorescent intensities to approx. 200 and 
250 F.U respectively. Paclitaxel treatment caused the greatest increase in fluorescent intensity, up to 
approx. 450 F.U, which is not surprising as paclitaxel is a classical apoptosis inducer and activates 
caspase-3. Both MBA and ABZ, and paclitaxel all caused significant increases in fluorescent intensity 
compared to control, however no statistical analysis was possible as only one replicate was obtained. 
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Figure 15: MBZ, ABZ and Paclitaxel cause increased caspase-3 activity. Caspase-3 activity 
measured by fluorescent intensity of HT-29 cells treated for 24hrs with MBZ (2µM), ABZ (2µM), 
paclitaxel (50nM), DMSO 0.1% v/v or left as untreated control using the caspase-3 specific substrate 
Ac-DEVD-AMC. Excitation wavelength – 380 nm; Emission wavelength – 400-440 nm. n = 1 
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4.3 Apoptosis vs Necrosis 
Following both 24 and 48 hr treatments, cells were double-stained with Annexin-V to identify 
external phosphatidylserine residues, markers of early apoptosis, and PI to detect cell membrane 
permeabilisation, a sign of necrosis, in order to suggest which route of cell death MBZ and ABZ 
cause. Following 24hr treatment, MBZ and ABZ caused approximate 25% decreases in the 
percentage of viable cells (negative for both Annexin V and PI) compared to control (P < 0.0001), 
similar to that of the positive control paclitaxel (Figure 16). MBZ and ABZ caused a significant 20% 
increase in the percentage of cells with phosphatidylserine exposure – a sign of early apoptosis – with 
22.83% of MBZ treated cells positive for Annexin V only and 24.17% of ABZ treated cells, whereas 
only 3.37% of control cells were positive (P < 0.0001). Paclitaxel also showed a large increase of 
20.72% of cells with phosphatidylserine exposure. Paclitaxel, MBZ and ABZ all showed small but 
significant increases in cells positive for both Annexin V and PI - an indicator of secondary/late 
apoptosis – MBZ; 5.78%, ABZ; 5.99%, paclitaxel; 7.94% vs Control; 2.12% (P < 0.0001). Cells 
positive for PI only due to membrane permeabilisation, an indicator of necrosis, were increased in 
MBZ and ABZ treatments only, compared to control, 3.58% and 3.48% vs 0.54% respectively. 
DMSO vehicle control produced no significant changes in any cell state compared to control. 
Forty-eight-hour treatments produced similar results to that of 24hr treatments, with significant 
reduction of the percentage of viable cells observed with MBZ, ABZ and paclitaxel compared to 
control (Figure 17). MBZ; 75.67%, ABZ; 74.97% and paclitaxel 74.54% vs control; 86.39% (P < 
0.0001). Interestingly, DMSO treatment resulted in a small but significant increase in the percentage 
of viable cells – 88.87% (P < 0.05). The percentage of cells positive for Annexin V only were also 
significantly increased following MBZ, ABZ and paclitaxel treatments compared to control. MBZ; 
19.50%, ABZ 19.53% and paclitaxel; 19.81% vs control; 4.00% (P < 0.0001). There were no 
significant differences in the percentage of cells positive for both Annexin V and PI following any 
treatment compared to control (P > 0.05). Surprisingly, MBZ and paclitaxel treatment resulted in 
small but statistically significant decreases in the percentage of cells positive for PI only, an indicator 
40 
 
of necrosis, MBZ; 0.80% and paclitaxel 0.72% vs control 3.52% (P < 0.05). Other than a 2.5% 
increase in the percentage of viable cells, DMSO again had no significant change on the percentage 
of cells stained with either Annexin V, PI or both, compared to control. 



























































1 0 0 C o n tro l
D M S O  0 .1 %  (v /v )
M B Z  (2 M )
A B Z  (2 M )
P a c lita x e l (5 0 n M )
* * * *
* * * *
* * * *
* * * *
 
Figure 16. MBZ, ABZ and Paclitaxel cause significant increases in phosphatidylserine 
exposure. Percentage of HT-29 cells in viable (Annexin V-/PI-), early apoptotic (Annexin V+/PI-), 
secondary/late necrotic (Annexin V+/PI+), or necrotic (Annexin V-/PI+) states, determined by staining 
with Annexin V and PI. Cells were treated for 24hrs with MBZ (2µM), ABZ (2µM), paclitaxel 
(50nM), DMSO 0.1% v/v or left as untreated control. Data represents mean ± SEM of three 
independent experiments carried out in triplicate, where each sample consisted of a minimum of 
50,000 stopping events. One-way ANOVAs were performed with a post-hoc Dunnett’s test 
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Figure 17. MBZ, ABZ and Paclitaxel cause significant increases in phosphatidylserine 
exposure. Percentage of HT-29 cells in viable (Annexin V-/PI-), early apoptotic (Annexin V+/PI-), 
secondary/late necrotic (Annexin V+/PI+), or necrotic (Annexin V-/PI+) states, determined by staining 
with Annexin V and PI. Cells were treated for 48hrs with MBZ (2µM), ABZ (2µM), paclitaxel 
(50nM), DMSO 0.1% v/v or left as untreated control. Data represents mean ± SEM of three 
independent experiments carried out in triplicate, where each sample consisted of a minimum of 
50,000 stopping events. One-way ANOVAs were performed with a post-hoc Dunnett’s test, 
comparing against untreated control, where p < 0.05 was considered statistically significant. *p < 





4.4  Sub-G1 
Another indicator of apoptosis is the fractionation of DNA content following treatment. This Sub-G1 
DNA content can be estimated using PI. Here, following both 24 and 48 hour treatments with MBZ, 
ABZ and paclitaxel, the percentage of cells with Sub-G1 DNA content were significantly increased 
compared to control (Figure 18). After 24hrs MBZ resulted in 13.84% (P = 0.001) of cells with Sub-
G1 DNA content, ABZ; 11.53% (P = 0.026), paclitaxel; 19.33% (P < 0.0001) vs control; 6.45%. 
DMSO caused no significant change to the percentage of cells with Sub-G1 DNA content, 6.11% (P 
> 0.05). 
Following 48hr treatment with MBZ, 21.96% (P < 0.0001) of cells contained Sub-G1 DNA content, 
ABZ; 15.33%b (P < 0.0001), paclitaxel; 23.10% (P < 0.0001), whereas control only contained 4.32%. 
DMSO again showed no significant difference to that of control, 5.12% (P > 0.05). 
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Figure 18. MBZ, ABZ and Paclitaxel cause significant increases in cells with Sub-G1 DNA 
content. Percentage of HT-29 cells with Sub-G1 DNA content, determined by PI fluorescence using 
flow cytometry, following 24 hr (left bar) and 48 hr (right bar) treatment with MBZ (2 µM), ABZ (2 
µM), paclitaxel (50 nM), DMSO (0.1% v/v) or untreated control. Data represent means ± SEM, of 
three separate experiments (n = 3) performed in triplicate, where each sample includes a minimum of 
50,000 stopping events. One-way ANOVAs were performed, with Dunnett’s post-hoc test comparing 
to respective untreated controls, where p < 0.05 was considered as statistically significant. *P < 0.05, 




4.5   Mitochondrial Membrane Potential (ΔΨm) 
HT-29 cells were treated with MBZ, ABZ, paclitaxel, DMSO or left untreated for 24 and 48 hrs and 
the percentage of cells with depolarised mitochondrial membrane potentials, indicative of apoptosis, 
were determined using the mitochondrial-targeted stain TMRE in conjunction with flow cytometry. 
In the 24 hr treatments there were no significant differences between both DMSO vehicle control 
(3.49 ± 0.38%) and D2 (4.70 ± 0.41 %) compared to control (3.36 ± 0.29%, p > 0.05). However, in 
MBZ, ABZ and paclitaxel treatments there were approximate 6-fold increases in the percentage of 
cells with depolarised mitochondrial membrane potentials compared to control. MBZ – 19.17 ± 
2.23%; ABZ – 18.12 ± 1.32%; paclitaxel – 18.68 ± 1.40%, all of which were statistically significant 
and gave p values less than 0.0001, (Figure 19). 
Cells exposed to the treatments for 48 hrs exhibited similar results to that of the 24 hr treatments. 
DMSO (3.87 ± 0.10%) showed no difference compared to control (4.79 ± 0.17%, p > 0.05), D2 (6.38 
± 0.23%) exhibited a slight increase compared to control however, this was not statistically significant 
(p > 0.05). MBZ, ABZ and paclitaxel similarly showed a large 4-fold increase in the percentage of 
cells with depolarised mitochondrial membrane potentials compared to control. MBZ – 15.74 ± 
1.14%; ABZ – 15.90 ± 1.60%; paclitaxel – 16.87 ± 0.78%, p < 0.0001 (Figure 19). 
The difference between the two treatment times in respect in control, DMSO and D2 treatments where 
there is a greater percentage of cells with depolarised mitochondrial membrane potentials in the 48 
hr group compared to the 24 hr group, may be attributed to a much larger population of cells as they 
had an additional 24 hrs to grow. Therefore, there would be a greater percentage of baseline cells with 
depolarised mitochondrial membrane potentials. On the other hand, there is a decrease in the 
percentage of cells with depolarised mitochondrial membrane potentials in the 48 hr treatment groups 
of ABZ, MBZ and paclitaxel compared to the 24 hr group. This may be explained by the increased 
exposure time of these cytotoxic agents on the cells, thereby killing more cells and decreasing the 

















































































* * * *
 
Figure 19. MBZ, ABZ and Paclitaxel cause depolarisation of the mitochondrial membrane 
potential (Ψ). Percentage of HT-29 cells with depolarised mitochondrial membrane potential (Ψ) 
determined by TMRE fluorescence intensity, following 24 hr (left bar) and 48 hr (right bar) treatment 
with MBZ (2 µM), ABZ (2 µM), paclitaxel (50 nM), DMSO (0.1% v/v) or untreated control. Data 
represent means ± SEM, of three separate experiments (n = 3) performed in triplicate, where each 
sample includes a minimum of 50,000 stopping events. One-way ANOVAs were performed, with 
Dunnett’s post-hoc test comparing to respective untreated controls, where p < 0.05 was considered 





4.6  Lysosomal and Outer Membrane Permeability 
Following treatment with MBZ, ABZ, paclitaxel, DMSO or untreated control for both 24 and 48 hrs, 
lysosomal and outer cell membrane permeability was assessed using the metachromatic dye AO, in 
conjunction with flow cytometry, which emits green fluorescence in monomeric forms bound to 
dsDNA, and red fluorescence when accumulated in acidic vesicles, i.e. lysosomes. 
Figure 20 shows the percentage of HT-29 cells with LMP following 24 and 48 hr treatments. Twenty-
four-hour treatment of MBZ, ABZ and paclitaxel all displayed large significant increases of cells with 
LMP, 36.28%, 36.76% and 24.16% respectively, vs control 3.81% (p < 0.0001). DMSO displayed no 
significant difference compared to control, 4.35% (p > 0.05). Forty-eight-hour treatment yielded 
similar results, with a notable increase in cells with LMP following paclitaxel treatment compared to 
24 hr treatment. MBZ – 35.01%; ABZ – 35.03%; paclitaxel – 34.17% vs control – 4.50% (p < 0.0001), 
whereas DMSO showed no significant difference, 4.79% (p > 0.05). 
Figure 21 shows the percentage of HT-29 cells with outer cell membrane permeabilisation following 
24 and 48 hr treatments, and closely matches the results seen in Figure 10 of cells with LMP. 
Following 24 hr treatment, MBZ, ABZ and paclitaxel showed significant increases in the percentage 
of cells with outer cell membrane permeabilisation compared to control. MBZ – 37.40%; ABZ – 
37.92%; paclitaxel – 24.20% vs control 4.29% (p < 0.0001), whereas DMSO showed no significant 
difference, 4.63% (p > 0.05). Following 48 hr treatment, MBZ – 34.18%; ABZ - 34.17%; paclitaxel 
35.76%, vs control 4.73% (p < 0.0001), with DMSO again showing no significant difference, 4.99% 
(p > 0.05). 
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Figure 20. MBZ, ABZ and Paclitaxel cause significant increases in cells with permeabilised 
lysosomal membranes. Percentage of HT-29 cells with lysosomal membrane permeabilisation 
determined by AO fluorescence intensity using the PE filter, following 24 hr (left bar) and 48 hr (right 
bar) treatment with MBZ (2 µM), ABZ (2 µM), paclitaxel (50 nM), DMSO (0.1% v/v) or untreated 
control. Data represent means ± SEM, of three separate experiments (n = 3) performed in triplicate, 
where each sample includes a minimum of 50,000 stopping events. One-way ANOVAs were 
performed, with Dunnett’s post-hoc test comparing to respective untreated controls, where p < 0.05 
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Figure 21. MBZ, ABZ and Paclitaxel cause significant increases in cells with permeabilised 
outer membranes. Percentage of HT-29 cells with lysosomal membrane permeabilisation 
determined by AO fluorescence intensity using the FITC filter, following 24 hr (left bar) and 48 hr 
(right bar) treatment with MBZ (2 µM), ABZ (2 µM), paclitaxel (50 nM), DMSO (0.1% v/v) or 
untreated control. Data represent means ± SEM, of three separate experiments (n = 3) performed in 
triplicate, where each sample includes a minimum of 50,000 stopping events. One-way ANOVAs 
were performed, with Dunnett’s post-hoc test comparing to respective untreated controls, where p < 







4.7  ROS  
Indirect measurement of ROS damage was assessed using the DTNB assay, which is used to 
determine the free sulfhydryl content of cells samples, which is decreased as a consequence of 
oxidation from ROS and can be calculated using the molar extinction coefficient (ε) of DTNB. 
Following 48 hr treatments, the free sulfhydryl concentration was significantly decreased in cells 
treated with; MBZ – 2.671 x 10-5 M (p = 0.0094); ABZ – 2.646 x 10-5 M (p = 0.0086) and paclitaxel 
- 2.539 x 10-5 M (p = 0.0058) vs control – 4.630 x 10-5 M (Figure 22). DMSO exhibited a small 
increase (4.857 x 10-5 M) compared to control but was not statistically significant. 
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Figure 22. MBZ, ABZ and Paclitaxel cause significant decreases in cellular free sulfhydryl 
content.  The concentration of free sulfhydryls (M) in HT-29 cells following 48 hr treatment with 
MBZ (2 µM), ABZ (2 µM), paclitaxel (50 nM), DMSO (0.1% v/v) or untreated control. Three 
independent experiments were carried out (n = 3), where each sample included the entire contents of 
one well of a 6-well plate seeded at 300,000 cells. Data were analysed using a One-way ANOVA 
with Dunnett’s post-hoc test comparing to untreated control, where p < 0.05 was considered 
statistically significant. **p < 0.01  
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4.8  Cell Cycle 
Cell cycle analysis was carried out on HT-29 cells treated with MBZ, ABZ, paclitaxel, DMSO or 
untreated control for 24 or 48 hrs, and assessed using PI staining in conjunction with flow cytometry. 
Following 24 hr treatments, MBZ, ABZ and paclitaxel exhibited significantly large increases in the 
percentage of cells in the G2/M phase compared to control (Figure 23 and 24). As shown in Figure 
11, MBZ, ABZ and paclitaxel treatments all lead to significant increases in cells with Sub-G1 content 
compared to control. Cells in the G2/M phase were significantly increased in; MBZ – 60.18%; ABZ 
– 58.68% and paclitaxel – 62.42%, vs control – 19.28% (p < 0.0001). DMSO showed no significant 
difference, 21.37% (p > 0.05). Subsequently, MBZ, ABZ and paclitaxel treated cells showed 
significant decreases in the percentage of cells in the G1 and S phases. MBZ – 2.67% (G1), 11.84% 
(S); ABZ – 3.52% (G1), 10.56% (S); paclitaxel – 1.78% (G1), 6.92% (S); vs control 45.02 (G1) (p < 
0.0001), 22.87% (S) (p < 0.0001). The percentage of cells in the >G2/M phase were also increased 
following treatment with MBZ – 11.53% (p = 0.0027) and ABZ – 15.57% (p < 0.0001), vs control 
6.53%. DMSO showed no significant difference at any cell cycle phase compared to control (p > 
0.05). 
Forty-eight-hour treatments produced similar results to that seen of the 24 hr treatments, with G2/M 
arrest being the most significant observation in the MBZ, ABZ and paclitaxel groups. Cells in the 
G2/M phase were significantly increased in; MBZ – 54.42%; ABZ – 64.03% and paclitaxel – 51.10%, 
vs control – 16.79% (p < 0.0001) (Figure 25). This again lead to subsequent decreases in the 
percentage of cells in G1 and S phases. MBZ – 4.01% (G1) (p < 0.0001), 5.54% (S) (p < 0.0001); 
ABZ – 2.33% (G1) (p < 0.0001), 3.50% (S) (p < 0.0001); paclitaxel – 1.97% (G1) (p < 0.0001), 
8.02% (S) (p = 0.0001); vs control – 51.84% (G1), 19.72% (S). The percentage of cells in the >G2/M 
phase were also increased following treatment with MBZ – 13.66% (p = 0.0006); ABZ – 14.06% (p 
= 0.0003) and paclitaxel – 15.72% (p < 0.0001). There were no significant differences following 48 








Figure 23. MBZ, ABZ and Paclitaxel cause G2/M arrest in cell cycle following 24hr treatment. 
Histogram analysis of cell cycle in HT-29 cells following 24 hr drug treatment. Control and DMSO 
vehicle control (0.1% v/v) displaying “normal” G1 peaks at approx. 50K PE-A intensity, which is 
significantly diminished following MBZ (2 µM), ABZ (2 µM) and paclitaxel (50 nM) treatments, 
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Figure 24. MBZ, ABZ and Paclitaxel cause G2/M arrest in cell cycle following 24hr treatment. 
Cell cycle analysis of HT-29 cells following 24 hr treatment with MBZ (2 µM), ABZ (2 µM), 
paclitaxel (50 nM), DMSO (0.1% v/v) or untreated control. DNA content was assessed using PI 
staining. Data represent mean ± SEM of the percentage of cells at each cell cycle stage (Sub-G1; G1; 
S; G2/M; >G2/M). Three independent experiments were conducted in triplicate with a minimum of 
50,000 stopping events for each sample. Data were analysed using a Two-way ANOVA with 
Dunnett’s post-hoc test comparing to untreated control, where p < 0.05 was considered statistically 
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Figure 25. MBZ, ABZ and Paclitaxel cause G2/M arrest in cell cycle following 48hr treatment. 
Cell cycle analysis of HT-29 cells following 48 hr treatment with MBZ (2 µM), ABZ (2 µM), 
paclitaxel (50 nM), DMSO (0.1% v/v) or untreated control. DNA content was assessed using PI 
staining. Data represent mean ± SEM of the percentage of cells at each cell cycle stage (Sub-G1; G1; 
S; G2/M; >G2/M). Three independent experiments were conducted in triplicate with a minimum of 
50,000 stopping events for each sample. Data were analysed using a Two-way ANOVA with 
Dunnett’s post-hoc test comparing to untreated control, where p < 0.05 was considered statistically 
significant. ***p < 0.001, ****p < 0.0001 
 
4.9 Tubulin Staining 
Figure 26 shows nuclear and microtubular staining of HT-29 cells following treatment with MBZ (2 
µM), ABZ (2 µM), paclitaxel (50 nM) or DMSO vehicle control (0.1% v/v) for 8 hrs. MBZ, ABZ 
and paclitaxel all produced smaller brighter nuclei indicating nuclear condensation, as pointed out by 
the red arrows. Alpha- and acetylated-alpha-tubulin staining displayed a decreased fluorescent 
intensity following MBZ and ABZ treatment compared to control and even more so compared to 
paclitaxel, which increased intensity of both alpha- and acetylated-alpha-tubulin staining compared 
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to control. This suggests that MBZ and ABZ promote depolymerisation of microtubules, whereas 












         
         
  
 






Figure 26: MBZ, ABZ and paclitaxel cause condensation of nuclei and disrupt microtubule networks. 
Fluorescent staining analysis of HT-29 cells treated with MBZ (2 µM), ABZ (2 µM), paclitaxel (50 nM) or 
DMSO vehicle control (0.1% v/v) for 8 hrs. Cells were stained with Hoechst 33342, anti-alpha-tubulin and 
anti-acetylated-alpha-tubulin and imaged using the Nikon AI-R inverted fluorescent microscope with Nikon 
Intensilight C-HGFI mercury lamp (Olympus, Japan) at 20x magnification, with consistent exposure. Red 




Chapter 5:  Discussion 
The overall aim of the first part of this project was to identify the mechanism of action by which the 
two compounds 4-thiazolecarboxylic acid, 4, 5-dihydro-2-(4-nitrophenyl)-methyl ester (D1) and 4-
thiazolecarboxylic acid, 2-(4-nitrophenyl)-methyl ester (D2) cause cytotoxicity in cancer cells. The 
original screening of these novel compounds and other analogues in a previous study, revealed that 
4-thiazolecarboxylic acid, 2-(4-nitrophenyl)-methyl ester (D2 (12c in the Lamb et al. paper)) and the 
structurally related 4-thiazolecarboxylic acid, 2-(4-aminophenyl)-methyl ester (D3 (13c in the Lamb 
et al. paper)) were the only analogues that exhibited cytotoxicity in cancer cells below 100 µM (Lamb 
et al., 2015). D2 (12c) caused a time-dependent decrease in cell viability of HT-29 cells at 24 hrs 
from 77% to 53% at 72 hrs, whereas D3 (13c) caused a decrease from 82% to 55% when cells were 
treated at 10 µM. These compounds were also cytotoxic towards MCF-7 breast cancer cells, again 
showing time-dependent decreases in cell viability over 72 hr (Lamb et al., 2015). From this initial 
study carried out by Lamb et al, these two compounds and another analogue (11c), untested at the 
time, 4-thiazolecarboxylic acid, 4, 5-dihydro-2-(4-nitrophenyl)-methyl ester (D1), identical to D2 
except lacking a double-bond in the thiazole ring, became the focus of a summer studentship project, 
where it was found, surprisingly, that only D1 and D2 were significantly cytotoxic in a range of cancer 
cell lines and D3 showed no significant biological activity. This summer project was then expanded 
into the current Master’s project, aiming to examine the mechanism of anticancer action in depth 
using a variety of in vitro assays and techniques. Unfortunately, during the current investigation, both 
compounds displayed significantly decreased cytotoxicity towards cancer cells, even with a new 
batch, and results seen in the previous summer project were unable to be replicated. This most likely 
suggested that the two compounds D1 and D2 had degraded in solution over time and had lost their 
biological activity. Following a newly synthesised batch of both compounds, the potencies exhibited 
were different to the first batch and again degraded and lost activity, leading the project to 
investigating a completely new set of compounds. 
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Results from the previous summer project showed that both compounds had cytotoxic effects in breast 
and colon cancer cells and had IC50 values ranging between 50 – 100 µM following 24 hr treatment. 
Subsequent experiments for the Master’s project were then carried out using a concentration of 50 
µM of both D1 and D2 to investigate their mechanism of action. These included a range of flow 
cytometry assays, cell viability assays and nuclear staining. However, throughout this stage it later 
appeared that the two compounds had lost activity and results were not as expected, and later dose-
response curves showed that the cytotoxic potency had in fact decreased. 
Early results from the summer project suggested that these compounds may kill cancer cells by 
induction of apoptosis. This led to investigating the involvement of caspases, crucial components of 
the apoptotic pathway, by using a pan-caspase inhibitor z-VAD-FMK in an MTT cell viability assay. 
Figure 7 shows three cancer cells lines treated with D2 alone and in conjunction with the caspase 
inhibitor at both 0.1 and 1.0 µM. D2 alone showed significant decreases in cell viability in all cell 
lines, similar to the positive control paclitaxel. The caspase inhibitor exhibited no significant 
decreases in cell viability in any of the cell lines at either concentration, however it also failed to 
reduce the decrease in cell viability when treated with D2, and produce a “rescuing” effect. These 
results suggest that D2 could be causing cytotoxicity through a different mechanism than apoptosis, 
and may be independent from caspase activation. However, separate experiments using the caspase 
inhibitor up to 10 µM and in conjunction with the classical apoptosis inducer cisplatin showed that at 
any concentration of the caspase inhibitor, cell viability could not be significantly rescued, and that 
is was more likely that the caspase inhibitor was dysfunctional and failed to inhibit caspases (results 
not shown). 
Cell cycle was also analysed, using propidium iodide to stain DNA content, as previous studies had 
suggested that structurally similar phenylthiazole compounds act through inhibition of tubulin 
polymerisation and lead to arrest of cell cycle at the G2/M phase and subsequent increase of 
hypodiploid sub-G1 phase cells, which is indicative of apoptosis (Lu et al., 2009; Yu et al., 2015). 
However, no G2/M arrest or increase in sub-G1 cells were observed in any of the cell lines (Figure 
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8). There were no significant changes in cell cycle following D1 or D2 treatment compared to control 
in MCF-7 cells. D1 exhibited a 5% decrease in G1-phase cells in MDA-MB-231 cells and a 7.5% 
increase in G1-phase cells and 5.6% decrease in S-phase cells in HT-29 cells. D2 had no significant 
effect in any cell line. These results suggest that both D1 and D2 have no significant effect on cell 
cycle and may not interact with tubulin polymerisation in the way that most MTAs do leading to 
G2/M arrest.  
Figure 9 and 10 show D1 and D2’s effects on mitochondrial and lysosomal membrane 
permeabilisation, using the fluorochromatic dyes TMRE and acridine orange, respectively. No 
significant changes from control were seen in either treatment in any of the cell lines, except a small 
decrease in the percentage of MDA-MB-231 cells with LMP following D2 treatment, which may 
result from error caused by manual gating during analysis. However most likely due to both 
compounds losing activity and thus not cytotoxic towards the cells at this stage. 
Cells were also stained with Hoechst 33342 to examine nuclear morphology and identify if any 
treatments induced chromatin condensation, a classical marker of apoptosis. Figure 11 shows that in 
MCF-7 and HT-29 cells D1 and D2 produced no obvious changes in nuclear morphology compared 
to control and DMSO vehicle-treated cells. In MDA-MB-231 cells there are smaller brighter nuclei 
in D1 and D2 treated cells, however these are also seen in both control and DMSO treated cells and 
most likely represent the large variation of cell/nucleus size and shape of this cell line rather than an 
effect from a treatment. 
Dose-response curves were carried out again after the previous experiments and revealed a rightward 
shift and decrease in potency of both D1 and D2 in all cancer cell lines (Figure 12). The 24 hr IC50 
values of D1 were much greater than 100 µM in all cell lines with the lowest seen in MDA-MB-231 
cells of 394 µM. D2 was slightly more potent with values also above 100 µM except in MCF-7 cells 
where the IC50 was approximately 66 µM. Both compounds showed relatively selective cytotoxicity 
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towards cancer cells as IC50 values were the highest in the non-transformed mesenchymal stem-cell 
line RCB2157, where D1 had an IC50 of 604 µM and D2 1223 µM. 
Altogether these results show that D1 and D2 cause decreases in cell viability in cancer cells measured 
using the MTT assay. However, evaluating markers of apoptosis and cell cycle, both compounds 
exhibited no largely significant changes compared to untreated control or DMSO vehicle control, 
despite preliminary results suggesting that an apoptotic mechanism is involved. This suggests that a 
number of possibilities could be occurring. Firstly, D1 and D2 both are cytotoxic and cause decreases 
in cell viability, which may be due to other cell death mechanisms and not involve the apoptotic 
pathway however, this seems unlikely. Secondly, D1 and D2 are not actually cytotoxic, but somehow 
interfere with MTT producing a false positive result – this could be solved by using different cell 
viability assays such as sulforhodamine B or crystal violet. Again, this is unlikely as results from the 
summer project indicated that the compounds were cytotoxic and acting through apoptotic pathways 
due to observing phosphatidylserine externalisation and nuclear condensation. Thirdly and most 
likely, D1 and D2 are cytotoxic and do cause cell death via an apoptotic pathway, but have degraded 
over time and have decreased potency, therefore 50 µM was of too low a concentration to see any 
effects and potentially the chemical structures of the compounds had changed thus losing activity 
altogether. 
Both D1 and D2 were obtained dissolved in 100% DMSO at stock concentrations of 10 mM and 
stored at room temperature for many months. In retrospect the compounds should have been given in 
a solid powder form, and dissolved into DMSO when required, as experiments were carried out over 
a period of multiple months and hence given longer exposure to the mild oxidative nature of DMSO, 
thus potentially resulting in the oxidation/degradation of the compounds. Previous studies have 
shown that the stability of compounds dissolved in DMSO greatly decrease over a period of 1 year. 
In one study the stability of approximately 7200 compounds stored as 20 mM DMSO solutions at 
room temperature was assessed. The probability of observing any one compound was 92% after 3 
months of storage at room temperature, 83% after 6 months, and 52% after 1 year in DMSO 
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(Kozikowski et al., 2003). Furthermore, the longer the compounds are stored in DMSO the greater 
the chance of them precipitating out, due to the hygroscopic nature of DMSO as it pulls water from 
the surrounding atmosphere (Waybright et al., 2009). A potential solution for this is the addition of a 
cosolvent(s) that is not hygroscopic such as glycerol. 
The second section of the project then focused on investigating two other compounds, mebendazole 
and albendazole. These two anthelmintic benzimidazoles are commonly prescribed to treat a range of 
worm infestations. Recently these drugs have shown promising results against cancer activity both in 
vitro and in vivo and look to be promising drug candidates to be repurposed for anticancer indication, 
with MBZ already in a range of clinical trials for treatment of gliomas (Pantziarka et al., 2014; Castro 
et al., 2016). These two drugs were of interest as their anthelmintic mechanism of action was well 
documented and due to the inhibition of tubulin polymerisation in gastrointestinal cells of helminths, 
however their anticancer effect was less understood but most likely involved alteration of tubulin. 
Similar to the investigation of D1 and D2, MBZ and ABZ were screened in three cancer cell lines 
and one non-transformed mesenchymal stem cell line over 24 and 48 hrs and mechanism of anticancer 
action investigated using a variety of flow cytometry assays, caspase-3 and ROS assays and 
fluorescent imaging.  
MBZ and ABZ both produced dose-dependent and time-dependent decreases in the cell viability of 
the three cancer cell lines HT-29, MCF-7, and MDA-MB-231, as well as in the mesenchymal stem 
cell line RCB2157 (Figures 13-14). MBZ and ABZ were observed to have the highest IC50 values in 
the mesenchymal stem-cell line compared to any of the cancer cell lines, suggesting that these drugs 
may be more selectively cytotoxic towards cancer cells. Of the cancer cell lines, both MBZ and ABZ 
exhibited low micromolar IC50 values and were most potent towards the HT-29 colorectal cancer cell 
line, with MBZ having 24 and 48 hr IC50 values of 1.3 ± 0.1 µM and 0.11 ± 0.07 µM respectively, 
and ABZ having 1.4 ± 0.1µM and 0.69 ± 0.42 µM respectively. For practical reasons, only one cell 
line was used to investigate the anticancer mechanism of action of MBZ and ABZ, with the HT-29 
cell line being chosen due to having the lowest IC50 values and potent cytotoxicity compared to the 
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other cancer cell lines. The concentration of 2 µM was used for both MBZ and ABZ for all further 
experiments based upon their respective IC50 values. 
A possible explanation to why MBZ and ABZ are more selective towards HT-29 cells may be due to 
the fact that they contain the BRAFV600E mutation encoding for a protein involved in the RAS 
signalling pathway associated with cellular growth. Somatic mutations in the BRAF gene have been 
described in almost 50% of malignant melanomas and many other cancers including colorectal 
carcinoma (CRC), ovarian and papillary thyroid carcinomas (Dhomen et al., 2007). The V600E is the 
most frequent BRAF mutation, accounting for approximately 80% of all reported mutations in CRC 
and is present in HT-29 cells, but not in MCF-7, MDA-MB-231 or RCB2157 cells (Davies et al., 
2002; Ahmed et al., 2013). Previous studies, including a large screening program using the NCI 60 
cell line library identified MBZ and ABZ as potential therapies for a range of CRC and identified 
their high affinities for these cell lines due to interaction with several protein kinases, in particular 
BRAF (Nygren et al., 2013). Another study found that MBZ has a higher affinity for mutant 
BRAFV600E (210 nM) over wild-type BRAF (230 nM), and that MBZ selectively inhibits BRAF in 
refractory NRASQ61K melanoma cells containing the V600E mutation, and suppresses growth in 
combination with trametinib – a MEK inhibitor (Simbulan-Rosenthal et al., 2017). This may be an 
additional pathway involved in cell death/cell growth however, the scope of this project remained 
focused on apoptotic/necrotic pathways and involvement with microtubules. 
Previous studies have suggested that MBZ and ABZ elicit their anticancer effects via induction of 
apoptosis in non-small cell lung cancer (NSCLC) and gastric cancer cell lines, exhibiting caspase 
activation, mitotic arrest, cytochrome c release and DNA fragmentation (Mukhopadhyay et al., 2002; 
Sasaki et al., 2002; Zhang et al., 2017). To examine whether MBZ and ABZ cause cell death through 
an apoptotic pathway in HT-29 cells, cleaved caspase-3 activity, phosphatidylserine exposure and 
fragmented sub-G1 DNA content were analysed. Mitochondrial and lysosomal membrane 
permeability were also assessed to identify whether either organelle was involved in the cell death 
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pathway. Paclitaxel was used as a positive control in all experiments as it is a well-known inducer of 
apoptosis, as well as being a classical MTA. 
Caspase-3 is an effector caspase involved in both the intrinsic and extrinsic pathways, where it is one 
of the last enzymes to be activated by cleavage, then carrying out degradation of cellular components, 
which result in morphological changes, and hence it is considered as a classical marker of apoptosis 
(Logue et al., 2008). Cleaved caspase-3 activity was measured using the fluorescent substrate Ac-
DEVD-AMC, which contains the selective amino acid sequence (DEVD) recognised by caspase-3 
allowing cleavage of the AMC (amido-4-methylcoumarin) fluorophore, which can then be measured 
using a fluorometer. Figure 15 shows caspase-3 activity by intensity of fluorescence at 440 nm 
following 24 hr treatment with MBZ, ABZ and paclitaxel. Paclitaxel treatment exhibited a 
significantly large increase in fluorescent intensity compared to control and DMSO, which came of 
no surprise as paclitaxel’s induction of cleaved caspase-3 is well documented (Oyaizu et al., 1999; 
Lu et al., 2005). MBZ appeared to significantly increase fluorescent intensity (~250 F.U (fluorescence 
units)) compared to control (~150 F.U), however not to the extent of paclitaxel (~450 F.U), with ABZ 
also increasing fluorescent intensity (~200 F.U) albeit less than MBZ. Unfortunately, this experiment 
was done only once, due to difficulties with standardising the assay, however the results still suggest 
that cleaved caspase-3 is involved and the death pathway may most likely be apoptotic. Previous 
studies have also confirmed increased cleavage of caspase-3 following treatment with 0.5 µM and 
1.0 µM MBZ in H460 and A549 lung cancer cells as well as in M-14 and SK-Mel-19 melanoma cells 
where cleavage of caspase-3 was evident as early as 6 hr after treatment (Sasaki et al., 2002; Doudican 
et al., 2008). ABZ at 1 µM has also previously shown increases in caspase-3 cleavage at 8, 24 and 48 
hr treatment in the same HT-29 colorectal cancer cell line (Pourgholami et al., 2005).  
Another classical marker of apoptosis is the externalisation of phosphatidylserine residues, which are 
usually restricted to the inner membrane layer, but become expressed on the surface of the cell 
whereby they are recognised by macrophages leading to the phagocytosis of apoptotic cells 
(Shiratsuchi et al., 1998). Using flow cytometry and annexin V-FITC, a dye which binds specifically 
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to phosphatidylserine residues, along with PI, a non-permeable DNA-binding dye, cells treated with 
MBZ and ABZ were categorised as viable, early or late apoptotic, or necrotic following 24 and 48 hr 
treatments. Figure 16 shows the state of cells following 24 hr treatment with MBZ, ABZ, paclitaxel, 
DMSO (vehicle only) or control. Treatment with MBZ or ABZ caused significant decreases in the 
viability of cells and increased the percentage of cells with phosphatidylserine externalisation, 
indicative of early apoptosis, by approximately 25% compared to control (3%), similar to that of 
paclitaxel treatment. The percentage of cells positive for both annexin V and PI, indicative of late or 
secondary apoptosis, was also increased following treatment with MBZ, ABZ and paclitaxel. The 
percentage of necrotic cells, being positive for PI alone, was also slightly increased following MBZ 
and ABZ treatment but not paclitaxel treatment. This may be due to inaccurate compensation with 
spill-over of annexin-V labelled cells into the PI filter as the two labels have emission wavelengths 
that overlap slightly (Annexin-V 518 nm; PI 617 nm). These significant increases in apparent 
secondary apoptotic and necrotic cells were not observed following 48 hr treatments, whereas a large 
20% increase in early apoptotic cells were still observed following treatments with MBZ, ABZ and 
paclitaxel (Figure 17). This suggests that along with paclitaxel, MBZ and ABZ cause significant 
increases in phosphatidylserine externalisation and further support their anticancer mechanism of 
action to involve an apoptotic pathway. This is also supported by a previous study where M-14 and 
SK-Mel-19 human melanoma cells were treated with 1 µM MBZ for 24 hrs and exhibited 25% and 
31% of cells positive for annexin-V staining, respectively (Doudican et al., 2008). ABZ has also 
previously been shown to increase annexin-V positive staining in SGC-7901 gastric cancer cells in a 
time- and concentration-dependent manner, also producing an approximate 20% increase in annexin-
V positive cells following 24 hr treatment with 1 µM ABZ (Zhang et al., 2017). Similar results have 
also been observed in vivo with ABZ (20 mg/kg) treatment increasing the percentage of apoptotic 
cells 5.4-fold compared to control (p < 0.05) in Ehrlich ascitic carcinoma (EAC) tumour cells grown 
in Balb-c mice (Castro et al., 2016). 
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Internucleosomal DNA fragmentation is another hallmark of apoptosis. As previously mentioned, 
apoptosis is characterised by the activation of a range of endonucleases, particularly caspase-3 
activated DNase (CAD), which once activated results in subsequent cleavage of nuclear DNA into 
internucleosomal fragments of roughly 180 base pairs and multiples thereof (360, 540 and so on) 
(Sakahira et al., 1998). Following fixation with 70% ethanol which also permeabilises cell 
membranes, cells were stained with the DNA-binding dye propidium iodide (PI) and apoptotic cells 
can be identified on DNA content frequency histograms as cells with fractional (“sub‐G1”) DNA 
content, commonly known as the Nicoletti assay (Lizard et al., 1997; Riccardi et al., 2006). Figure 
18 shows the percentage of treated cells with sub-G1 DNA content. Similar to paclitaxel, both MBZ 
and ABZ exhibited time-dependent increases in the percentage of cells with sub-G1 DNA content. 
After 48 hr treatment, ABZ exhibited 15% of sub-G1 cells, with MBZ resulting in 22% of cells, 
similar to that of paclitaxel with 23% of sub-G1 cells, compared to 4% of control (p < 0.0001). MBZ 
(0.5 µM) has also previously been shown to time-dependently increase the percentage of subdiploid 
cells in H460 and A549 lung cancer cells. At 48 h, 35% of H460 cells and 15% of A549 cells were 
in the sub-G1 phase, indicating that MBZ induced cell death after mitotic arrest (Sasaki et al., 2002). 
There is lack of sub-G1 analyses of ABZ treatment in cancer cells in the literature. However, in the 
same HT-29 colorectal cancer cell line using gel electrophoresis following 48 hr treatment with 1 µM 
ABZ, a DNA ladder effect was demonstrated indicating DNA fragmentation and activation of 
endonucleases (Pourgholami et al., 2005).  
With sufficient evidence of caspase-3 activation, phosphatidylserine externalisation and DNA 
fragmentation, it is clear that both MBZ and ABZ cause cell death via an apoptotic pathway in HT-
29 colorectal cancer cells. Further analysis of cell cycle, mitochondrial and lysosomal membrane 
permeabilisation, ROS formation and tubulin alteration may lead to a better understanding as to how 
MBZ and ABZ induce apoptosis, and whether it is through an intrinsic or extrinsic pathway. 
Mitochondrial membrane permeabilisation (MMP) is a universal feature of cell death and is often 
considered as the “point of no return” in the cascade of events leading to apoptosis. The 
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permeabilisation of the outer membrane is a sign of the intrinsic apoptotic pathway, due to the 
formation of MACs, composed of pro-apoptotic proteins Bax and/or Bak, causing the subsequent 
release of cytochrome c and other factors into the cytosol triggering the commitment step of the 
mitochondrial apoptotic cascade (Dejean et al., 2005; Dejean et al., 2006). The loss of the 
mitochondrial membrane potential (ΔΨm) is also associated with the permeabilisation of the outer 
mitochondrial membrane due to the loss of cytochrome c. Cytochrome c is essential for producing 
ΔΨm because it promotes the pumping the protons into the mitochondrial intermembrane space as it 
shuttles electrons from Complex III to Complex IV along the electron transport chain. Cytochrome c 
is released from the mitochondrial intermembrane space into the cytosol during apoptosis. This 
impairs its ability to shuttle electrons between Complex III and Complex IV and results in rapid 
dissipation of ΔΨm. Loss of ΔΨm is therefore closely associated with cytochrome c release during 
apoptosis and is often used as a surrogate marker for cytochrome c release in cells. The net negative 
charge across a healthy mitochondrion is maintained at approximately -180 mV, which can be 
detected by staining cells with positively charged dyes such as tetramethylrhodamine ethyl ester 
(TMRE). TMRE emits a red fluorescence that can be detected by flow cytometry or fluorescence 
microscopy and the level of TMRE fluorescence in stained cells can be used to determine whether 
mitochondria in a cell have high or low ΔΨm (Crowley et al., 2016b).  
Figure 19 shows the percentage of cells with depolarised ΔΨm/permeabilised mitochondrial 
membranes following treatment with MBZ, ABZ or paclitaxel. Approximately 20% of cells treated 
with either MBZ, ABZ or paclitaxel for 24 hrs exhibited depolarised ΔΨm, 6-fold higher than that of 
either control of DMSO treated cells. Similar results were seen following 48 hr treatment, however 
slightly less percentage of depolarised cells than 24 hrs, due to increased treatment exposure resulting 
in a greater number of dead cells. These results suggest that both MBZ and ABZ may induce apoptosis 
via the intrinsic pathway involving the permeabilisation of mitochondrial membranes, similar to that 
of paclitaxel which has also previously been shown to cause MMP and subsequent depolarisation of 
the ΔΨm in cancer cells (Ahn et al., 2004). MMP induced by MBZ treatment in cancer cells has 
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currently not been directly examined in the literature however, these results are further supported by 
MBZ exhibiting significant dose-dependent (0.2 – 1.0 µM) increases in cytochrome c release in A549, 
H460 and H1299 lung cancer cells following 12 and 24 hr treatments (Mukhopadhyay et al., 2002; 
Sasaki et al., 2002). ABZ’s direct effect on ΔΨm has previously been examined in MCF-7 breast 
cancer cells where it was shown that 100 µM ABZ significantly (p < 0.1) decreased ΔΨm compared 
to untreated control by approximately 20% following 6 hr treatment, which was restored when treated 
with 5 mM of the antioxidant N-acetylcysteine (NAC) (Castro et al., 2016). There were no significant 
changes using concentrations less than 100 µM however, this may be due to the fact that MCF-7 cells 
are less sensitive to ABZ as seen in this present study (Figure 13-14), and that exposure for 6 hr may 
not have been a long enough time to witness any changes using lower concentrations of ABZ. The 
authors also describe that ABZ treatment increases the ratio of mitochondrial Bax/Bcl-xL, which 
induces Bax activation and cytochrome c release from the mitochondria, thereby confirming that ABZ 
induces the mitochondrial-associated pathway of apoptosis (Castro et al., 2016).  
To determine whether lysosomes played a role in the anticancer mechanism of action of MBZ and 
ABZ, LMP was measured in conjunction with cellular membrane permeabilisation using the 
dichromatic dye acridine orange. Figure 20 shows the percentage of cells with LMP following 24 and 
48 hr treatment with MBZ, ABZ and paclitaxel, whereas Figure 21 shows the percentage of cells with 
permeabilised outer cell membranes. Following 24 hr treatment with either MBZ or ABZ there is a 
significant 33% increase in the percentage of cells with LMP compared to control (p < 0.0001, which 
proved to be even greater than paclitaxel (~20%). Forty-eight-hour treatment exhibited similar 
significant increases in the percentage of cells with LMP, however slightly less with MBZ and ABZ 
but a greater time-dependent increase was seen with paclitaxel (Figure 13). The reason for this may 
be similar to that of Figure 19 and MMP, with the longer treatment period resulting in more dead 
cells and less cells in the process of dying and with a measurable LMP. However, interestingly 
paclitaxel treatment caused a time-dependent increase in the percentage of cells with LMP. The 
results seen in Figure 21 involving the percentage of cells with permeabilised outer cell membranes 
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almost exactly match that of the LMP results (Figure 20) with both MBZ and ABZ treatment, as well 
as with paclitaxel. All three treatments caused significant cell membrane permeabilisation to the same 
extent as LMP at both 24 and 48 hrs. This suggests that both MBZ and ABZ treatments do not target 
the lysosome and promote permeabilisation directly, which would lead to lysosomal-triggered 
apoptosis, as the percentage of LMP would be greater than cell membrane permeabilisation at any 
one time. Results rather suggests that LMP is a symptom of apoptosis triggered elsewhere, 
independent to the lysosome, as the percentage of cell membrane permeabilisation is virtually equal 
to that of the percentage of cells with LMP. Also, the results seen from MBZ and ABZ treatment are 
similar to that of paclitaxel, which is not a lysosomotropic compound and does not target the lysosome 
directly to cause apoptosis, but rather exhibits LMP following apoptosis induction (Bröker et al., 
2004). To further confirm that MBZ and ABZ are not directly targeting the lysosome and inducing 
LMP, earlier time points should be examined in the future such as at 3, 6 and 12 hours. Currently, 
this is believed to be the only assessment of MBZ and ABZ treatment on LMP in cancer cells. 
Limited studies have been performed on assessing ROS in cells treated with MBZ and ABZ. As both 
mitochondrial and lysosomal membranes have been determined to permeabilise following MBZ and 
ABZ treatment, releasing their contents into the cytosol, it was hypothesised that there would be an 
increase in the production of ROS, as mitochondria are the major ROS-generating organelle and 
lysosomes contain H2O2 as well as the main pool of chelatable iron, capable of catalysing Fenton-
type reactions. The DTNB assay which measures free sulfhydryl content, as an indirect measurement 
of ROS formation was used, as ROS such as hydroxyl and peroxyl radicals, superoxide and hydrogen 
peroxide cause damage by reacting with macromolecules like lipids, DNA and proteins where they 
are able to oxidise sulfhydryl groups (Liou et al., 2010). MBZ, ABZ and paclitaxel all exhibited 
significant decreases in free sulfhydryl content to nearly 50% of both control and DMSO vehicle-
control following 48 hr treatments (Figure 22). This suggested that both MBZ and ABZ cause 
increases in ROS and may contribute to their mechanism of anticancer action, however as this was 
only carried out following 48 hrs of treatment, it is likely that this increase in ROS activity (as 
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measured by decreases in free sulfhydryl content) is merely a symptom of apoptosis that has already 
been induced by the permeabilisation and leakage of mitochondria and lysosomes. Paclitaxel has 
previously been shown to produce apoptosis in leukaemia cells via intracellular ROS generation and 
activation of the JNK pathway, independent to its microtubule action and may suggest that MBZ and 
ABZ may behave similarly (Meshkini et al., 2012). However, there is very little examination of MBZ 
and ABZ on ROS production in cancer cells in the literature, but one previous study has shown that 
ABZ induces oxidative stress promoting DNA fragmentation and triggering apoptosis and inducing 
cell death (Castro et al., 2016).  Future studies with MBZ and ABZ should investigate earlier time-
points, with additional assays that measure ROS production more directly such as with the DCFDA 
assay, as well as using antioxidants like NAC and examine whether they can rescue the effects seen 
with MBZ and ABZ treatments. 
As MBZ and ABZ are known to inhibit tubulin polymerisation in helminths and likely to interact 
with tubulin in cancer cells, the effect of treatment on cell cycle was then assessed. Other MTAs such 
as paclitaxel and nocodazole are well known to affect the cell cycle and cause arrest leading to the 
induction of apoptosis (Blajeski et al., 2002). Figures 23-25 show the effects of MBZ, ABZ and 
paclitaxel on cell cycle following 24 and 48 hr treatments. At both time-points all three treatments 
exhibited significant changes in the percentage of cells in sub-G1, G1, S, G2/M and >G2/M phases 
compared to untreated control and DMSO vehicle control. As already discussed, all three treatments 
caused significant time-dependent increases in the percentage of cells in the sub-G1 phase. However, 
the most important results seen here are the significantly large increases in the percentage of cells in 
the G2/M phase following treatment with either MBZ or ABZ, at both 24 and 48 hrs, similar to that 
of the paclitaxel treatment. These large increases in the percentage of cells in the G2/M phase lead to 
a subsequent decrease in the percentage of cells in both the G1 and S phases. Not surprisingly, 
paclitaxel caused significant G2/M arrest, which has been well documented before in a range of 
cancer cell lines including ovarian, breast, lung and glioma, and caused hyperstabilisation of 
microtubule dynamics leading to mitotic arrest in the G2/M phase and thus causing subsequent 
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induction of apoptosis (Shu et al., 1997; Vikhanskaya et al., 1998; Das et al., 2001; Han B., 2016). 
However, it is worth noting that paclitaxel may also cause induction of apoptosis in a manner 
independent to G2/M arrest, and still kill cells via the microtubule system but uncoupled from mitotic 
arrest and cause apoptosis during other phases of the cell cycle, as well as the possibility of causing 
apoptosis through altering gene expression (Fan, 1999). From these results it is clear to see that both 
MBZ and ABZ cause significant increases in cells arrested in the G2/M phase, similar to paclitaxel, 
indicating that they interact with microtubule dynamics and cause mitotic arrest leading to induction 
of apoptosis. This is supported by previous studies, which have also observed significant G2/M cell 
cycle arrest following treatment with MBZ or ABZ.  In the H460 lung cancer cell line MBZ (0.5 µM) 
treatment caused significant time-dependent increases in cells arrested at the G2/M phase 
(Mukhopadhyay et al., 2002; Sasaki et al., 2002). The authors found that the cells were blocked at 
the G2-M phase 12 h after MBZ treatment before undergoing apoptosis. Cells were rounded and 
partly detached after 12 h of MBZ treatment. However, after 24 h of treatment, cell shrinkage 
occurred, and nuclear bodies were evident; the cells subsequently underwent apoptosis. After 48 h of 
MBZ treatment, ~60% of the cells had undergone apoptosis with characteristic nuclear fragmentation. 
Similar results have also been observed in melanoma and triple-negative breast cancer cell lines, in 
particular refractory NRASQ61K melanomas where MBZ (0.1 µM) caused significant (p < 0.01) 
increases in cells at the G2/M phase following 8 hr treatment, and also in SUM159PT cells where 
MBZ (0.35 µM) caused a significant (p < 0.001) increase in the percentage of cells in the G2/M phase 
following 24 hr treatment (Simbulan-Rosenthal et al., 2017; Zhang et al., 2019). ABZ has also 
previously been shown to induce G2/M arrest in a dose-dependent manner (0 – 1 µM) over 24 hrs in 
the human gastric cancer cell lines MKN-45, SGC-7901 and MKN-28 (Zhang et al., 2017). ABZ (20 
mg/kg) also significantly (p < 0.001) increased the percentage of EAC cells in the G2/M phase, 
obtained from inoculated balb-c mice, treated once daily for nine days (Castro et al., 2016). ABZ (1 
µM) also exhibited time-dependent increases in the percentage of HT-29 cells in the G2/M phase, 
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where during the first 24 hrs cells in the G2/M phase increased from 1.3 ± 0.3% to 88.1 ± 0.9% 
(Pourgholami et al., 2005). 
There is a high likelihood that the reason behind the G2/M arrest caused by ABZ and MBZ treatment 
is due to interactions with microtubules, such as promoting depolymerisation. However, there is still 
the possibility of microtubule-independent causes, such as altered gene expression and 
inhibition/induction of microtubule-associated proteins (MAPs) and other cell cycle regulators such 
as cyclins and cyclin-dependent kinases (CDKs). Unfortunately, no such assessments were carried 
out in this study but previous studies have given understanding as to how MBZ and ABZ affect these 
other potential targets. In the NSCLC cells A549 and H460 it was found that MBZ (0.5 µM) induced 
depolymerisation of tubulin and inhibited normal spindle formation in NSCLC cells, resulting in 
mitotic arrest at the G2/M phase and cell death (Sasaki et al., 2002). MBZ treatment also induced 
changes in the expression of cell cycle-regulatory proteins and initiated a phosphorylation cascade 
resulting in the phosphorylation of MPM-2 and Cdc25C in NCSLC cells. These dynamic changes in 
protein expression and modification are consistent with mitotic arrest (Morris et al., 2000). During a 
normal cell cycle, the progression of G2 cells to M phase is triggered by the activation of MPF, whose 
activity is predominantly regulated by the phosphorylation/dephosphorylation of CDK1, as well as 
the synthesis, degradation and subcellular localisation of cyclin B1. Previous studies have found that 
the M/G1 transition requires the degradation of cyclin B1 (Surana et al., 1993; Yamano et al., 1996). 
Therefore, high levels of cyclin B trigger cell cycle arrest during the M phase; however, they also 
prevent cell division (Gallant et al., 1992; Choi et al., 2011). Treatment of SGC-7901 cells with 
various concentrations of ABZ (0.25-1.0 µM) for 24 h dose-dependently led to increased expression 
of cyclin B1 up to two-fold higher than control, which may be a plausible reason for the M-phase 
arrest observed (Zhang et al., 2017). However, in the same study ABZ was observed to cause 
depolymerisation of microtubules and prevent spindle formation and this is likely to be the main 
reason behind the G2/M arrest. 
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Identifying G2/M arrest following ABZ/MBZ treatment is not sufficient enough evidence to indicate 
the interference with microtubule dynamics. Therefore, using fluorescent microscopy and antibodies 
for alpha-tubulin – a main component of the tubulin dimer that polymerises to form microtubules – 
and acetylated-alpha-tubulin – an indicator of stabilised microtubules – it was possible to observe the 
effects of both ABZ and MBZ treatment on microtubules of HT-29 cells, and compare that to 
untreated control as well as paclitaxel. Figure 26 shows treated cells stained with Hoechst 33342, 
alpha-tubulin and ac-alpha-tubulin antibodies. Staining was not quantified however, but provides a 
visual indication as to how MBZ and ABZ affect microtubule and nuclear morphology. From the 
nuclear staining, both MBZ and ABZ treatments show brighter smaller nuclei compared to control, 
indicating the condensation of nuclei, a classical marker of apoptosis. This is also seen with paclitaxel 
treatment, however interestingly also observed in only paclitaxel treatment were cells with multiple 
nuclei, which is common in cells exiting mitosis following treatment with taxanes or vinca alkaloids 
as they often develop lobulated nuclei and multiple micronuclei, hinting at the possible differences 
between MBZ/ABZ and other MTAs (Jordan et al., 1992; Theodoropoulos et al., 1999). Both MBZ 
and ABZ produced diminished fluorescent intensities of cells stained with both alpha-tubulin and ac-
alpha-tubulin compared to control. Whereas paclitaxel treatment produced much greater intensities 
with both alpha-tubulin and ac-alpha-tubulin stained cells compared to control. This suggests that 
MBZ and ABZ may destabilise microtubules and promote depolymerisation as ac-alpha-tubulin 
staining is a marker of stabilised cells, which is very prominent in paclitaxel treated cells as paclitaxel 
is a well-known hyperstabiliser of microtubule dynamics (Al-Bassam et al., 2012). The decreased 
intensity of cells stained with the anti-alpha-tubulin following MBZ and ABZ treatment was 
unexpected, as it was only hypothesised that they would only decrease the intensity of the stabilised 
acetylated form. However, in paclitaxel treated cells there was a higher intensity of fluorescence of 
alpha-tubulin, therefore it may be possible that the antibody only optimally binds or fluoresces when 
tubulin is in the polymerised form, hence giving a low fluorescence intensity following MBZ and 
ABZ treatment as these drugs promote depolymerisation. Previous studies have also shown similar 
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results with MBZ treatment using fluorescent microscopy. In A549 lung cancer cells following 14 hr 
MBZ (0.5 µM) treatment, many mitotic cells had abnormally reduced numbers of spindles or had 
monopolar (monoaster) spindles. These spindle abnormalities were very similar to those in cells 
treated with nocodazole, a similar structurally-related benzimidazole, but completely different from 
the aggregated spindles present in paclitaxel-treated cells (Sasaki et al., 2002). In the melanoma cell 
lines melan-a, M-14, and SK-Mel-19, cells were treated with MBZ (0.5 µM) for 14 hrs and stained 
with anti-alpha-tubulin. Overall microtubular network disarray in melan-a, M-14, and SK-Mel-19 
cells were observed following MBZ treatment, characterized by diffuse staining. This is in contrast 
to the vehicle-treated melanocytes and melanoma cells which displayed discrete networks of 
microtubule structure. Furthermore, mitotic figures, when observed in MBZ-treated cells, had an 
abnormal appearance with improperly aligned chromosomes (Doudican et al., 2008). ABZ treatment 
has also been shown to cause similar results in the human gastric cancer cell line SGC-7901 (Zhang 
et al., 2017). The untreated control SGC-7901 cells showed an organised distribution of microtubules; 
treated cells that were exposed to 0.5 µM ABZ for 18 hr displayed irregular microtubule formation. 
In interphase cells, microtubules were less well dispersed with a fuzzy network structure, and 
appeared thicker and depolymerised. Mitotic cells were notably increased in size and primarily 
featured multipolar spindles and uncompressed chromosomes. 
These microscopy results, in conjunction with results from previous literature, suggest that both MBZ 
and ABZ affect tubulin structure in cancer cells and promote depolymerisation, in contrast to 
paclitaxel which affects tubulin dynamics by promoting polymerisation and stabilisation. This has 
been further confirmed with both MBZ and ABZ treatment producing increases in the 
soluble/insoluble tubulin ratios in cancer cells, i.e. decreasing the amount of insoluble polymerised 
tubulin - an indicator of tubulin depolymerisation. In A549 lung cancer cells the ratio of 
depolymerised: polymerised tubulin was 0.75 ± 0.12 for MBZ-treated cells, 1.46 ± 0.25 for 
nocodazole-treated cells, 0.16 ± 0.03 for paclitaxel-treated cells, and 0.42 ± 0.06 for DMSO-treated 
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control cells (Sasaki et al., 2002). Even 4 hrs of incubation with MBZ was enough to significantly 
enhance the depolymerisation of tubulin in A549 cells compared to vehicle-control cells, but the 
magnitude of this effect by MBZ was significantly less than that by nocodazole, which is a well-
known potent microtubule depolymerising agent (Blajeski et al., 2002). Paclitaxel further decreased 
the ratio in contrast to MBZ and nocodazole treated cells, which is expected due to paclitaxel 
promoting polymerisation and causing greater amounts of insoluble microtubules. ABZ has also been 
shown to significantly decrease the insoluble fraction (polymerised) of microtubules in SGC-7901 
cells in a dose-dependent (0.25 – 1 µM) manner over 24 hrs, also confirming the depolymerising 
nature of ABZ (Zhang et al., 2017).  
Future directions for this study would also include confirming the destabilisation of microtubules by 
MBZ and ABZ, which has already been carried out and proven in vitro as previously mentioned 
(Blajeski et al., 2002; Sasaki et al., 2002; Bai et al., 2011; Zhang et al., 2017), as well as identifying 
the binding site to which MBZ and ABZ interact with microtubules. The microtubule binding site of 
MBZ and likely that of ABZ as well, has already been confirmed to be the same as the colchicine site 
in helminths and has more recently been shown to be the same with mammalian tubulin (Friedman et 
al., 1980; Laclette et al., 1980; Russell et al., 1995; Jornet et al., 2016). Using laser flash photolysis, 
Jornet et al showed that MBZ and related anticancer benzimidazoles act by binding the β-subunit of 
tubulin before dimerisation with α-tubulin with subsequent blocking of microtubule formation.  
The next step with MBZ and ABZ would include animal studies and looking at the anticancer effects 
in vivo. Fortunately, a few studies have already proven the anticancer potential of both MBZ and ABZ 
in vivo, with MBZ (p.o) treatment significantly inhibiting tumour growth in human adrenocortical 
carcinoma and lung cancer cells implanted in mice (Mukhopadhyay et al., 2002; Martarelli et al., 
2008). ABZ (150 mg/kg, i.p.) has also been shown to significantly (p < 0.001) suppress tumour 
growth in a xenograft model of peritoneal carcinomatosis using nude mice implanted with HT-29 
cells (Pourgholami et al., 2005). MBZ (50 mg/kg, p.o) and ABZ (150 mg/kg, p.o) have both exhibited 
significant inhibition in cancer cell growth in both in vitro and in vivo models of glioblastoma 
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multiforme (GBM), with MBZ proving to be more efficacious most, likely due to the difference in 
bioavailability in these models (Bai et al., 2011). The limited solubility of ABZ and MBZ in water 
and organic solvents greatly affects absorption and behaviour in the body, with ABZ reported to have 
between 5-10% bioavailability whereas MBZ has been reported to have between 5-10% and 17-22% 
in healthy human volunteers, with both drugs undergoing extensive first-pass metabolism (Dayan, 
2003). In GBM cell lines, MBZ displayed cytotoxicity, with half-maximal inhibitory concentrations 
ranging from 0.1 to 0.3 µM, much more potent than in the colorectal HT-29 cancer cells. MBZ 
disrupted microtubule formation in GBM cells, and in vitro activity was correlated with reduced 
tubulin polymerisation. Subsequently, the authors showed that MBZ significantly extended mean 
survival up to 63% in syngeneic and xenograft orthotopic mouse glioma models (Bai et al., 2011). 
Based on the evidence supplied, it is in contention that human clinical trials of MBZ in a range of 
cancer types is warranted, with MBZ preferred over ABZ due to being more efficacious and having 
a better safety profile. The known pharmacokinetics, relatively low toxicity (even with extended high-
dosing protocols), low cost, and strong pre-clinical evidence make this an ideal candidate for re-
purposing. Currently, there are two early phase clinical trials getting under way, both in glioma and 
a relatively recent trial in GI cancer and cancer of unknown origin NCT01729260, NCT01837862, 
NCT03628079. In addition to these, the evidence suggests that candidate cancer types to take to 
human trial include: melanoma (Doudican et al., 2013), non-small cell lung cancer (Sasaki et al., 
2002), adrenocortical cancer (Martarelli et al., 2008), and colon cancer (Mukhopadhyay et al., 2002). 
5.1 Conclusion 
Overall, the results from this study have identified that both MBZ and ABZ produce cell death via an 
intrinsic apoptotic pathway, stemming from cell cycle arrest at the G2/M phase due to the 
depolymerisation of microtubules. Significant caspase-3 activation, phosphatidylserine 
externalisation and DNA fragmentation were all observed following treatment with MBZ or ABZ 
suggesting that cell death is via an apoptotic pathway, supported by other previous studies. 
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Mitochondrial membrane permeabilisation suggests that apoptosis follows the intrinsic pathway, 
rather than the receptor-mediated extrinsic pathway, with evidence of increased ROS production. 
Lysosomal membrane permeabilisation is also evident with both MBZ and ABZ treatments, however 
its involvement remains to be further elucidated as at the time points tested it appears to be a symptom 
of already induced apoptosis rather than the causative effect. Finally, both MBZ and ABZ cause 
mitotic arrest at the G2/M phase of the cell cycle, indicative of MTAs, and appear by fluorescent 
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